研究者詳細 - 瀧澤　淳

2026/07/02 更新

写真a

タキザワ　ジユン

瀧澤　淳

TAKIZAWA Jun

所属

教育研究院医歯学系医学系列准教授
医歯学総合研究科生体機能調節医学専攻内部環境医学准教授

外部リンク

学位

博士（医学）（ 1997年3月新潟大学）

研究分野

ライフサイエンス / 血液、腫瘍内科学

経歴（researchmap）

新潟大学医歯学総合病院血液内科病院教授

2019年6月 - 現在

　詳細を見る

researchmap
新潟大学医歯学総合研究科生体機能調節医学専攻内部環境医学准教授

2013年7月 - 現在

　詳細を見る

researchmap
新潟大学医歯学総合研究科生体機能調節医学専攻器官制御医学助教

2009年12月 - 2013年6月

　詳細を見る

researchmap
新潟大学超域研究機構助教

2008年1月 - 2009年11月

　詳細を見る

researchmap
新潟大学医歯学総合病院生命科学医療センター特任助教

2007年8月 - 2007年12月

　詳細を見る

researchmap

経歴

新潟大学医歯学総合研究科　生体機能調節医学専攻　内部環境医学准教授

2013年7月 - 現在
新潟大学医歯学総合研究科　生体機能調節医学専攻　器官制御医学助教

2009年12月 - 2013年6月
新潟大学超域研究機構助教

2008年1月 - 2009年11月
新潟大学医歯学総合病院　生命科学医療センター特任助教

2007年8月 - 2007年12月

学歴

新潟大学大学院医学研究科

1993年4月 - 1997年3月

　詳細を見る

国名：日本国

researchmap
新潟大学医学部医学科

1984年4月 - 1990年3月

　詳細を見る

国名：日本国

researchmap

所属学協会

日本臨床腫瘍学会

　詳細を見る

researchmap
日本輸血細胞治療学会

　詳細を見る

researchmap
日本癌学会

　詳細を見る

researchmap
日本リンパ網内系学会

　詳細を見る

researchmap
日本内科学会

　詳細を見る

researchmap
日本血液学会

　詳細を見る

researchmap

▶ 全件表示

委員歴

日本血液学会問題作成委員

2023年9月 - 2025年8月

　詳細を見る

researchmap
日本リンパ腫学会診療保険委員

2018年 - 現在

　詳細を見る

researchmap
日本血液学会関東甲信越地方会幹事

2017年3月 - 現在

　詳細を見る

researchmap
日本血液学会評議員

2015年9月 - 現在

　詳細を見る

researchmap
日本リンパ腫学会評議員

2014年 - 現在

　詳細を見る

researchmap

論文

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan 査読

Hirotaka Matsui, Jun Takizawa, Kensuke Kojima, Tetsuzo Tauchi, Chiaki Ikeda, Yu Aruga, Hiroki Sakamoto, Risa Takenaka, Jinhaeng Park, Tetsuo Morita, Hiromichi Matsushita, Ritsuro Suzuki

International Journal of Hematology 123 ( 5 ) 678 - 685 2025年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Abstract

Measurable residual disease (MRD), defined as the persistence of minimal levels of leukemic cells following therapeutic intervention, serves as a pivotal prognostic biomarker in patients with chronic lymphocytic leukemia (CLL). We conducted a multicenter, cross-sectional study to assess MRD in Japanese patients with relapsed or refractory CLL. All patients received venetoclax-based therapy for 24 months. MRD in peripheral blood (PB) and bone marrow was assessed by multicolor flow cytometry using surface markers, including kappa and lambda light chains of surface immunoglobulins. The primary and secondary outcomes were the proportions of patients who achieved undetectable MRD (uMRD, < 10 <sup>−4</sup> CLL cells) and low-MRD (< 10 <sup>−2</sup> and ≥ 10 <sup>−4</sup> CLL cells) after 24 months of venetoclax treatment. From June 2023 to December 2024, 60 patients were enrolled, and 51 were analyzed. The median age was 78 years, and 68.6% were male. Thirty-four of 51 patients (66.7%) achieved uMRD, and 8 (15.7%) achieved low-MRD in PB after at least 24 months of venetoclax treatment. Assessment of MRD in PB by flow cytometry is helpful for evaluating treatment response, informing clinical decision-making, and predicting long-term outcomes in clinical practice. Further analyses are warranted to investigate the use of MRD in treatment decision-making and prognostication.Kindly check the inserted city in affiliations 5 and 9.The city names were corrrected.

DOI： 10.1007/s12185-025-04149-z

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-025-04149-z
A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL 査読

Jun Takizawa, Isao Yoshida, Yoshiaki Ogawa, Tomomi Toubai, Shigeru Kusumoto, Mitsumasa Watanabe, Natsumi Ogawa, Natsuko Satomi, Yasuko Nishimura, Hideyuki Honda, Brenda Chyla, Koji Izutsu

International Journal of Hematology 123 ( 3 ) 375 - 384 2025年11月

　詳細を見る

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Abstract

The development of effective and safe therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in Japan remains a key focus of research. We conducted a phase 2, open-label, multicenter, non-comparative study to evaluate the safety and efficacy of fixed-duration venetoclax plus ibrutinib in 10 patients with previously untreated CLL/SLL (7 CLL/3 SLL). The primary endpoint was the rate of complete remission (CR)/CR with incomplete marrow recovery (CRi) assessed by the independent review committee (IRC). The median age was 72.5 (range 61–77) years. The IRC-assessed CR/CRi rate was 60.0% (95% confidence interval: 26.2–87.8%), exceeding the pre-specified efficacy threshold of 10% and meeting the primary endpoint. The median venetoclax treatment duration was 11.0 (range 2.1–17.7) months. At a median follow-up of 20.6 months, the secondary endpoints of median progression-free and overall survival were not estimated. The overall undetectable measurable residual disease rate was 60.0%. All patients experienced treatment-emergent adverse events (TEAEs), including 7 (70.0%) with grade 3/4 and 2 (20.0%) with serious TEAEs, respectively, and 1 discontinued venetoclax because of a TEAE (increased blood creatine phosphokinase). These findings suggest that venetoclax plus ibrutinib has a favorable benefit–risk profile with high efficacy and manageable safety.

DOI： 10.1007/s12185-025-04114-w

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-025-04114-w
Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study 査読

Koji Izutsu, Mitsumasa Watanabe, Tomomi Toubai, Taku Tsukamoto, Dai Maruyama, Takahiro Kumode, Noriko Fukuhara, Natsumi Ogawa, Natsuko Satomi, Yasuko Nishimura, Hideyuki Honda, Brenda Chyla, Jun Takizawa

International Journal of Hematology 123 ( 2 ) 225 - 232 2025年11月

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Abstract

This phase 2 study (NCT05105841) evaluated the safety and efficacy of a fixed-duration 12-cycle regimen of venetoclax plus obinutuzumab in Japanese patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The primary efficacy endpoint was the complete remission (CR)/complete remission with incomplete marrow recovery (CRi) rate, assessed by an independent review committee (IRC) according to the 2008 International Workshop on CLL criteria. Ten patients (6 male, 4 female; 9 CLL, 1 SLL) with a median age of 69.5 years (range 52–76) received venetoclax for a median duration of 11.3 months (range 9.2–12.4). The IRC-assessed CR/CRi rate based on the best overall response was 90.0% (95% confidence interval 55.5%, 99.7%). All patients experienced at least one treatment-emergent adverse event (TEAE), and three patients (30.0%) experienced at least one serious TEAE. The most common TEAEs included infusion-related reactions (60.0%), decreased neutrophil count (50.0%), and nausea (40.0%). Nine patients (90.0%) experienced TEAEs related to venetoclax, while all ten patients (100.0%) had TEAEs related to obinutuzumab. One patient (10.0%) developed COVID-19 pneumonia, necessitating the discontinuation of venetoclax. These findings demonstrate the high efficacy and manageable safety profile of venetoclax plus obinutuzumab in this patient population.

DOI： 10.1007/s12185-025-04095-w

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-025-04095-w
Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. 査読国際誌

Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata, Yasuo Ejima, Dai Maruyama, Nobuko Kubota, Takeshi Maeda, Jun Takizawa, Nobuhiro Hiramoto, Masahiro Takeuchi, Rika Sakai, Noriko Fukuhara, Senzo Taguchi, Naoko Asano, Motoko Yamaguchi, Ritsuro Suzuki

Leukemia 39 ( 4 ) 909 - 916 2025年4月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19-90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014-2017 vs. 50.7% for 2018-2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.

DOI： 10.1038/s41375-025-02527-4

PubMed

researchmap
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. 査読国際誌

Kazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Akinao Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Akiko Meguro, Yoshihiro Kin, Yosuke Minami, Daigo Hashimoto, Takahiro Nishiyama, Satoko Shimada, Yasufumi Masaki, Masataka Okamoto, Yoshiko Atsuta, Hitoshi Kiyoi, Ritsuro Suzuki, Shigeo Nakamura, Tomohiro Kinoshita

EClinicalMedicine 80 103078 - 103078 2025年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi). METHODS: We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165). FINDINGS: With a median follow-up of 7.1 years (interquartile range 5.6-8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%-80%) and OS was 78% (95% CI 61%-89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1). INTERPRETATION: Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients. FUNDING: This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.

DOI： 10.1016/j.eclinm.2025.103078

PubMed

researchmap
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study. 査読国際誌

Jun Takizawa, Takanori Teshima, Daisuke Ennishi, Satoshi Ichikawa, Ritsuro Suzuki, Akira Kojima, Yusuke Takahashi, Nobuya Hayashi, Hisashi Kawasumi, Kosho Murayama, Patricia Cheung, Toshio Kawata, Koji Izutsu

Leukemia & lymphoma 65 ( 11 ) 1586 - 1594 2024年11月

　詳細を見る

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

This report focuses on part 3 of a multicenter, open-label, phase 1 study (NCT03198650) assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of acalabrutinib plus obinutuzumab in Japanese patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL). Ten patients were included; median age was 68 years. With a median treatment duration of 27.2 months, treatment-emergent adverse events (AEs) occurred in all patients (grade ≥3, 70%), and the most common AEs were anemia and headache (40% each). One patient had a grade 4 AE of neutropenia (the only dose-limiting toxicity). PK results suggested no marked effects of concomitant obinutuzumab treatment on the exposure of acalabrutinib. PD assessment indicated that combination therapy provided >98% Bruton tyrosine kinase (BTK) occupancy. Overall response rate (ORR) was 100% with median duration of response (DoR) and median progression-free survival (PFS) not reached. Treatment with acalabrutinib plus obinutuzumab was generally safe and efficacious in adult Japanese patients with TN CLL.

DOI： 10.1080/10428194.2024.2370436

PubMed

researchmap
Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. 査読

Motoko Yamaguchi, Noriko Fukuhara, Jun Takizawa, Kenji Ishitsuka, Akihiko Yokohama, Kana Miyazaki, Yuma Nato, Satoshi Ichikawa, Masaki Mitobe, Kodai Shima, Yuri Miyazawa, Koji Izutsu, Ritsuro Suzuki, Hirokazu Nagai, Naoya Nakamura

Journal of clinical and experimental hematopathology : JCEH 2024年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Alemtuzumab is recommended as first-line and second-line therapies for T-cell prolymphocytic leukemia (T-PLL). This study retrospectively evaluated the efficacy and safety of alemtuzumab in nine Japanese patients with T-PLL at five participating institutions who were treated between January 2015 and August 2023. The median age at first administration of alemtuzumab was 72 years (range, 39 to 78). Two patients were treatment naïve, and seven had been treated with a median of one (range, 1 to 3) prior systemic therapy. Six patients were refractory to their most recent therapy. Three patients completed 12 weeks of treatment. The overall response rate and the complete response (CR) rate were 78% and 11%, respectively. Among the six patients who achieved a partial response, two achieved clinical CR but did not undergo bone marrow examination. One patient also achieved clinical CR but did not undergo CT or bone marrow examination for response evaluation. The median progression-free survival time was 8.1 months (95% confidence interval, 0.9 to 18.6). Three patients received readministration of alemtuzumab monotherapy after disease progression. There were no treatment-related deaths. The grade 3 or 4 nonhematologic adverse events included infusion reaction (grade 3, n = 2), cytomegalovirus reactivation (grade 3, n = 2), and pulmonary edema (grade 3, n = 1). One patient experienced Epstein‒Barr virus-positive diffuse large B-cell lymphoma 15 months after the last dose of alemtuzumab. These results confirm that the efficacy and safety of alemtuzumab monotherapy in Japanese patients are comparable to those previously reported.

DOI： 10.3960/jslrt.24028

PubMed

researchmap
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. 査読国際誌

Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto

Cancer science 2024年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Triplet regimen comprising proteasome inhibitors, immunomodulatory drugs, and dexamethasone (DEX) is a recommended induction/consolidation therapy for multiple myeloma (MM) patients eligible for transplant. In this Japanese phase II study conducted from 2017 to 2019, newly diagnosed MM patients aged 20-65 received four induction cycles with bortezomib (Bor), lenalidomide (Len), and DEX (VRD), followed by Bor and high-dose melphalan with autologous stem cell rescue. Subsequently, they underwent four consolidation cycles with carfilzomib, Len, and DEX (KRD), followed by Len maintenance until disease progression. A total of 141 patients were analyzed. In an intent-to-treat population, the complete or better response post induction was 19.9%, rising to 39.7%, 58.9%, and 62.4% after transplant, consolidation, and 1-year maintenance, respectively. With a median follow-up of 38 months, the 3-year progression-free survival (PFS) rate was 83.5% and the 3-year overall survival rate was 92.5%. Severe adverse events (≥grade 3) occurred in ~30% of patients; however, there was no treatment-related mortality. These findings clearly showed the tolerability and effectiveness of this protocol. Nevertheless, patients with high-risk cytogenetics showed a trend toward lower 3-year PFS than those without (77.8% vs. 89.4%, p = 0.051), and ultra-high-risk cytogenetics (≥2 high-risk cytogenetics) had an even worse prognosis, with 61.2% 3-year PFS. To overcome this situation, a more potent treatment strategy incorporating novel agents such as the CD38-antibody should be assessed in future studies.

DOI： 10.1111/cas.16158

PubMed

researchmap
Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study 査読

Jun Takizawa, Ritsuro Suzuki, Koji Izutsu, Toru Kiguchi, Hideki Asaoku, Yoshio Saburi, Taro Masunari, Atae Utsunomiya, Kengo Takeuchi, Naoya Nakamura, Koichi Ohshima, Michaela Gruber, Ulrich Jäger, Sadao Aoki, Junji Suzumiya

International Journal of Hematology 119 ( 6 ) 686 - 696 2024年3月

　詳細を見る

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

DOI： 10.1007/s12185-024-03741-z

researchmap

その他リンク： https://link.springer.com/article/10.1007/s12185-024-03741-z/fulltext.html
Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients. 国際誌

Yasumasa Shimasaki, Hiroaki Miyoshi, Keisuke Kawamoto, Noriaki Yoshida, Tatsuzo Mishina, Kazutaka Nakashima, Teppei Imamoto, Takeshi Sugio, Eriko Yanagida, Takeharu Kato, Kyohei Yamada, Mai Takeuchi, Takaharu Suzuki, Mayuko Moritsubo, Takuya Furuta, Yoshitaka Imaizumi, Jun Takizawa, Koji Kato, Junji Suzumiya, Ritsuro Suzuki, Koichi Ohshima

Cancer medicine 2024年1月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

AIM: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes. METHODS: In this study, we compared the clinicopathological features of PTCL-NOS in a Japanese cohort, classified using an IHC algorithm. RESULTS: One hundred patients with PTCL-NOS were categorized as having PTCL-TBX21 (n = 55), PTCL-GATA3 (n = 24), or PTCL-unclassified (n = 21). When comparing PTCL-TBX21 and PTCL-GATA3, PTCL-TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity-related genes, such as PD-L1, LAG3, and IDO1, in PTCL-TBX21 than in PTCL-GATA3. PTCL-GATA3 had significantly worse overall survival (OS) than those with PTCL-TBX21 (p = 0.047), although a similar tendency was observed for progression-free survival (PFS) (p = 0.064). PTCL-GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09-3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93-4.61; p = 0.074). In the PFS analysis, PTCL-GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08-3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07-5.11; p = 0.032). CONCLUSION: The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.

DOI： 10.1002/cam4.6793

PubMed

researchmap
YAP1/TAZ activity maintains vascular integrity and organismal survival. 国際誌

Shun Uemura, Masayuki Yamashita, Kazumasa Aoyama, Takako Yokomizo-Nakano, Motohiko Oshima, Miki Nishio, Masayoshi Masuko, Jun Takizawa, Hirohito Sone, Yasuhiro Yamada, Akira Suzuki, Atsushi Iwama

Biochemical and biophysical research communications 619 117 - 123 2022年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Radiation therapy is one of the major treatment modalities for patients with cancers. However, ionizing radiation (IR) damages not only cancer cells but also the surrounding vascular endothelial cells (ECs). Hippo pathway effector genes Yap1 and Taz are the two transcriptional coactivators that have crucial roles in tissue homeostasis and vascular integrity in various organs. However, their function in adult ECs at the steady state and after IR is poorly understood. Here, we report sex- and context-dependent roles of endothelial YAP1/TAZ in maintaining vascular integrity and organismal survival. EC-specific Yap1/Taz deletion compromised systemic vascular integrity, resulting in lethal circulation failure preferentially in male mice. Furthermore, EC-specific Yap1/Taz deletion induced acute lethality upon sublethal IR that was closely associated with exacerbated systemic vascular dysfunction and circulation failure. Consistent with these findings, RNA-seq analysis revealed downregulation of tight junction genes in Yap1/Taz-deleted ECs. Collectively, our findings highlight the importance of endothelial YAP1/TAZ for maintaining adult vascular function, which may provide clinical implications for preventing organ injury after radiation therapy.

DOI： 10.1016/j.bbrc.2022.06.050

PubMed

researchmap
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. 国際誌

Kana Miyazaki, Ritsuro Suzuki, Masahiko Oguchi, Senzo Taguchi, Jun Amaki, Takeshi Maeda, Nobuko Kubota, Dai Maruyama, Yasuhito Terui, Nodoka Sekiguchi, Jun Takizawa, Hiroyuki Tsukamoto, Tohru Murayama, Toshihiko Ando, Hiroshi Matsuoka, Masatoshi Hasegawa, Hideho Wada, Rika Sakai, Yoshihiro Kameoka, Norifumi Tsukamoto, Ilseung Choi, Yasufumi Masaki, Kazuyuki Shimada, Noriko Fukuhara, Takahiko Utsumi, Nobuhiko Uoshima, Yoshitoyo Kagami, Naoko Asano, Yasuo Ejima, Naoyuki Katayama, Motoko Yamaguchi

Hematological oncology 40 ( 4 ) 667 - 677 2022年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 and 2013 in a nationwide retrospective study in Japan were updated and analyzed. At a median follow-up of 8.4 years, the 5-year overall survival (OS) and progression-free survival (PFS) were 71% and 64%, respectively, in 140 localized ENKTL patients who received radiotherapy-dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) in clinical practice. Nine (6.4%) patients experienced second malignancies. In 155 localized ENKTL patients treated with RT-DeVIC, 10 (6.5%) experienced CNS relapse (median, 12.8 months after diagnosis). In five of them, the events were confined to the CNS. Nine of the 10 patients who experienced CNS relapse died within 1 year after CNS relapse. Multivariate analysis identified gingival (hazard ratio [HR], 54.35; 95% confidence interval [CI], 8.60-343.35) and paranasal involvement (HR, 7.42; 95% CI, 1.78-30.89) as independent risk factors for CNS relapse. In 80 advanced ENKTL patients, 18 received steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment. Patients who received SMILE as their first-line treatment tended to have better OS than those who did not (p = 0.071). Six (7.5%) advanced ENKTL patients experienced isolated CNS relapse (median, 2.6 months after diagnosis) and died within 4 months of relapse. No second malignancies were documented in advanced ENKTL patients. In the entire cohort, the median OS after first relapse or progression was 4.6 months. 12 patients who survived 5 years after PFS events were disease-free at the last follow-up. Of those, 11 (92%) underwent hematopoietic stem cell transplantation. Our 8-year follow-up revealed the long-term efficacy and safety of RT-DeVIC and SMILE. The risk of CNS relapse is an important consideration in advanced ENKTL.

DOI： 10.1002/hon.2977

PubMed

researchmap
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma 査読国際誌

Yasuhito Terui, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Hirohiko Shibayama

Cancer Science 112 ( 7 ) 2845 - 2854 2021年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2 , rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography-computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT.

DOI： 10.1111/cas.14937

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.14937
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia 査読

Koji Izutsu, Tomohiro Kinoshita, Jun Takizawa, Suguru Fukuhara, Go Yamamoto, Yasuo Ohashi, Junji Suzumiya, Kensei Tobinai

Japanese Journal of Clinical Oncology 51 ( 3 ) 408 - 415 2021年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Objective</title>
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is not approved for CLL. We investigated the efficacy and safety of FCR in this single-arm, multicenter study designed as a bridging study to the CLL8 study by the German CLL Study Group.

</sec>
<sec>
<title>Methods</title>
The study enrolled previously untreated patients with CLL of Binet stage B or C with active disease. Patients with a Cumulative Illness Rating Scale score of ≤6 and creatinine clearance of ≥70 ml/min were eligible. Patients received 6 cycles of FCR every 28 days and were followed for up to 1 year.

</sec>
<sec>
<title>Results</title>
Seven patients were enrolled. The best overall response rate according to the 1996 NCI-WG Guidelines, the primary endpoint of the study, was 71.4% (95% confidence interval, 29.0–96.3%), with one patient achieving complete response. No deaths or progression occurred during follow-up. The main adverse event was hematotoxicity. CD4-positive T-cell count decreased in all patients; most patients showed no reduction in serum immunoglobulin G.

</sec>
<sec>
<title>Conclusion</title>
Although the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-naïve fit Japanese patients with CD20-positive CLL.

</sec>
<sec>
<title>Clinical trial number</title>
JapicCTI-132285.

</sec>

DOI： 10.1093/jjco/hyaa215

researchmap
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. 国際誌

Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno

Hematological oncology 39 ( 1 ) 51 - 59 2021年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiuxetan (90 Y-IT) after re-induction therapy with BR in patients with previously treated FL. This study included adult patients with relapsed FL who had undergone one or two prior therapies. Re-induction therapy with BR was administered every 4 weeks up to 4-6 cycles. If patients achieved at least partial response, 90 Y-IT was administered as consolidation therapy. The primary endpoint was 2-year progression-free survival (PFS) after consolidation. A total of 24 FL patients (median age 60 years) who had undergone one (n = 17) or two (n = 7) prior treatments received BR. After BR therapy, 22 patients proceeded to consolidation with 90 Y-IT, resulting in an overall 88% response rate to the protocol treatment. Within a median observation period of 46.8 months, the estimated 2-year PFS rate after the consolidation among the 22 patients receiving 90 Y-IT was 59% (95% confidence interval [CI], 38%-77%). Patients whose remission after previous treatment had lasted ≥2 years had a significantly higher 2-year PFS rate than patients whose remission after previous treatment had been <2 years (68% vs. 33%, Wilcoxon p = 0.0211). Major adverse events during the protocol treatment and within 2 years after the consolidation were hematological toxicities, but they were generally acceptable. Consequently, the estimated 2-year overall survival after the consolidation was 95% (95% CI, 74%-99%). In conclusion, in a subset of patients with previously treated FL, 90 Y-IT consolidation after BR re-induction conferred a durable remission, indicating that consolidation therapy using 90 Y-IT may be a novel therapeutic option for patients with relapsed FL (UMIN000008793).

DOI： 10.1002/hon.2809

PubMed

researchmap
DA-EPOCH-R therapy for high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements in a patient with renal dysfunction 査読

Masaki Mitobe, Keisuke Kawamoto, Takaharu Suzuki, Tatsuya Suwabe, Yasuhiko Shibasaki, Masayoshi Masuko, Kanako Inoue, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

Journal of Clinical and Experimental Hematopathology 61 ( 1 ) 42 - 47 2021年

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Society for Lymphoreticular Tissue Research

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive and safe regimens for patients with renal dysfunction are unknown. Herein, we report the successful use of DA-EPOCH-R therapy for double-hit lymphoma in a 64-year-old man with renal dysfunction. The patient had lymphoma-induced bilateral ureteral obstruction. Although renal dysfunction remained after removing the obstruction using R-CHOP therapy, we completed six cycles of DA-EPOCH-R therapy without any major adverse events. DA-EPOCH-R therapy may be a safe regimen for renal dysfunction patients.

DOI： 10.3960/jslrt.20043

PubMed

researchmap
Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR)

Jun Takizawa, Koji Izutsu, Hirokazu Nagai, Kenjiro Fukase, Maki Nakamura, Masahisa Jinushi, Junji Suzumiya

Journal of Clinical and Experimental Hematopathology 61 ( 3 ) 126 - 134 2021年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3960/jslrt.20044

Web of Science

researchmap
Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)

Koji Izutsu, Junji Suzumiya, Jun Takizawa, Kenjiro Fukase, Maki Nakamura, Masahisa Jinushi, Hirokazu Nagai

Journal of Clinical and Experimental Hematopathology 61 ( 3 ) 135 - 144 2021年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3960/jslrt.20056

Web of Science

researchmap
Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma 査読国際誌

Ryo Kazama, Hiroaki Miyoshi, Mai Takeuchi, Kohta Miyawaki, Kazutaka Nakashima, Noriaki Yoshida, Keisuke Kawamoto, Eriko Yanagida, Kyohei Yamada, Takeshi Umeno, Takaharu Suzuki, Koji Kato, Jun Takizawa, Masao Seto, Koichi Akashi, Koichi Ohshima

Cancer Science 111 ( 7 ) 2608 - 2619 2020年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

The interaction between CD47 and signal-regulatory protein-α (SIRPα) inhibits phagocytosis, thus affecting the clinical outcomes of neoplastic diseases. Although CD47 upregulation is associated with poor prognosis in several malignancies, the effect of SIRPα expression and its coexpression with CD47 remains unclear. This study aimed to investigate the clinicopathologic effect of CD47 and SIRPα expression in diffuse large B-cell lymphoma (DLBCL). Immunostaining of 120 biopsy samples showed that CD47 is primarily expressed in tumor cells, whereas SIRPα is expressed in nonneoplastic stromal cells, mostly macrophages. CD47high cases showed higher MYC protein expression and lower MYC translocation. The SIRPαhigh cases presented significantly shorter overall survival (OS) and progression-free survival (PFS) than SIRPαlow cases in the activated B-cell (ABC) subtype of DLBCL (P = .04 and P = .02, respectively). Both CD47high and SIRPαhigh presented significantly shorter OS and PFS than other cases among all DLBCL patients (P = .01 and P = .004, respectively), and the ABC type (P = .04 and P = .008, respectively) but not the germinal center B-cell type. Both CD47high and SIRPαhigh yielded a constant independent prognostic value for OS and PFS in multivariate analysis (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.20-7.43; P = .02; and HR, 2.87; 95% CI, 1.42-5.85; P = .003, respectively). To the best of our knowledge, this is the first study to report that combinatorial CD47 and SIRPα expression is a potential independent prognostic factor for DLBCL. Evaluation of CD47 and SIRPα expression could be useful before CD47 blockade therapy.

DOI： 10.1111/cas.14437

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.14437
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? 査読

Junji Suzumiya, Jun Takizawa

International Journal of Hematology 111 ( 5 ) 642 - 656 2020年5月

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

DOI： 10.1007/s12185-020-02867-0

researchmap

その他リンク： http://link.springer.com/article/10.1007/s12185-020-02867-0/fulltext.html
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial 査読国際誌

Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Masataka Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Tohru Izumi, Yoshihiro Kin, Kunihiro Tsukasaki, Daigo Hashimoto, Masaaki Yuge, Atsumi Yanagisawa, Yachiyo Kuwatsuka, Satoko Shimada, Yasufumi Masaki, Nozomi Niitsu, Hitoshi Kiyoi, Ritsuro Suzuki, Takashi Tokunaga, Shigeo Nakamura, Tomohiro Kinoshita

The Lancet Oncology 21 ( 4 ) 593 - 602 2020年4月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier BV

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. METHODS: PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan. Eligible patients had untreated histologically confirmed IVLBCL, were aged 20-79 years, had an Eastern Cooperative Group performance status of 0-3, and had no apparent CNS involvement at diagnosis. Patients received three cycles of R-CHOP (rituximab 375 mg/m2 intravenously on day 1 [except cycle one, which was on day 8]; cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2·0 mg] intravenously on day 1 of cycle one and day 2 of cycles two and three; and prednisolone 100 mg/day orally on days 1-5 of cycle one and days 2-6 of cycles two and three) followed by two cycles of rituximab with high-dose methotrexate (3·5 g/m2 intravenously on day 2 of cycles four and five) every 2 weeks and three additional cycles of R-CHOP. Intrathecal chemotherapy (methotrexate 15 mg, cytarabine 40 mg, and prednisolone 10 mg) was administered four times during the R-CHOP phase. The primary endpoint was 2-year progression-free survival. Efficacy analyses were done in all enrolled patients; safety analyses were done in all enrolled and treated patients. The trial is registered in the UMIN Clinical Trials Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165); the trial is ongoing for long-term follow-up. FINDINGS: Between June 16, 2011, and July 21, 2016, 38 patients were enrolled, of whom 37 were eligible; one patient was excluded because of a history of testicular lymphoma. Median follow-up was 3·9 years (IQR 2·5-5·5). 2-year progression-free survival was 76% (95% CI 58-87). The most frequent adverse events of grade 3-4 were neutropenia and leucocytopenia, which were reported in all 38 (100%) patients. Serious adverse events were hypokalaemia, febrile neutropenia with hypotension, hypertension, and intracerebral haemorrhage (reported in one [3%] patient each). No treatment-related deaths occurred during protocol treatment. INTERPRETATION: R-CHOP combined with rituximab and high-dose methotrexate plus intrathecal chemotherapy is a safe and active treatment for patients with IVLBCL without apparent CNS involvement at diagnosis, and this regimen warrants future investigation. FUNDING: The Japan Agency for Medical Research and Development, the Center for Supporting Hematology-Oncology Trials, and the National Cancer Center.

DOI： 10.1016/s1470-2045(20)30059-0

PubMed

researchmap
Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. 査読国際誌

Takaharu Suzuki, Hiroaki Miyoshi, Joji Shimono, Keisuke Kawamoto, Fumiko Arakawa, Takuya Furuta, Kyohei Yamada, Eriko Yanagida, Mai Takeuchi, Masao Seto, Hirohito Sone, Jun Takizawa, Koichi Ohshima

Pathology international 70 ( 5 ) 280 - 286 2020年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Primary splenic low-grade B-cell lymphoma of the red pulp comprises hairy cell leukemia (HCL) and splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U). SPLL-U is a rare disease that includes subtypes of a hairy cell leukemia-variant (HCL-v), splenic diffuse red pulp small B-cell lymphoma (SDRPL) and other types that are known as narrow sense SPLL-U (SPLL-U-NS). Notably, limited information is available regarding the BRAF mutation (V600E) and cyclin D3 expression in subtypes of SPLL-U. Therefore, we performed a pathological analysis of the BRAF mutation (V600E) and characterized pathological features of SPLL-U. We reviewed the pathological findings of 12 SPLL-U cases. The 12 cases considered included two cases of HCL-v, six cases of SPLL-U-NS and four undetermined cases. The BRAF mutation (V600E) was detected in three cases, which were all SPLL-U-NS. Cases with the BRAF mutation (V600E) have increased levels of CD103 expression and decreased cyclin D3 and cyclin D1 expression compared with cases that lacked the BRAF mutation. These findings suggest that the BRAF mutation might play a significant role in SPLL-U. Therefore, the significance of the BRAF mutation should be evaluated via genomic or transcriptional analyses of a large cohort of SPLL-U patients.

DOI： 10.1111/pin.12909

PubMed

researchmap
The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study 査読国際誌

Jun Ominato, Tokuhide Oyama, Hiroyuki Cho, Naoya Shiozaki, Hajime Umezu, Jun Takizawa, Takeo Fukuchi

BMJ Open Ophthalmology 4 ( 1 ) e000295 - e000295 2019年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BMJ

<sec><title>Objective</title>This study aimed to examine the natural course and relapse rate of IgG4-related ophthalmic disease (IgG4-ROD) after debulking surgery in Japanese patients.

</sec><sec><title>Methods and analysis</title>This retrospective review included patients with IgG4-ROD who did not undergo further treatment following debulking surgery. The patients were diagnosed between January 2009 and December 2018 at the Department of Ophthalmology and Pathology, Niigata University Medical and Dental Hospital. The main outcome measures included postoperative IgG4-ROD recurrence rate and differences between patients with and without recurrent disease.

</sec><sec><title>Results</title>Fifteen patients (six male, 9 female; 61.8±16.2 years) were included. Twelve patients (80.0%) had dacryoadenitis disease and three patients (20.0%) had orbital fat tissue disease. About 70%–100% of the lesion was resected in the debulking surgery and the pathological diagnosis was rendered. A definitive diagnosis was made in 13 cases (86.7%) and a probable diagnosis in 2 cases (13.3%). Patients were followed up for 39.0±25.5 months following operation. All patients had lesion volume reduction and patients with dacryoadenitis had eyelid swelling improvement after surgery. Two patients (13.3%) had disease recurrence and six patients (40.0%) had extraophthalmic lesions. There was no statistically significant difference in clinical features between relapsed and non-recurring cases.

</sec><sec><title>Conclusion</title>We observed a 13.3% relapse rate following debulking surgery in patients with IgG4-ROD who did not undergo further treatment. This rate is lower than the documented relapse rate of 30%–70% following oral prednisolone therapy. Therefore, debulking surgery may be a treatment option for IgG4-ROD.

</sec>

DOI： 10.1136/bmjophth-2019-000295

PubMed

researchmap
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. 査読国際誌

Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N

Annals of hematology 98 ( 7 ) 1647 - 1655 2019年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s00277-019-03689-9

Scopus

PubMed

researchmap

その他リンク： http://orcid.org/0000-0002-5974-7614
Memory B cell pool of autoimmune pulmonary alveolar proteinosis patients contains higher frequency of GM-CSF autoreactive B cells than healthy subjects. 査読国際誌

Nei T, Urano S, Motoi N, Hashimoto A, Kitamura N, Tanaka T, Nakagaki K, Takizawa J, Kaneko C, Tazawa R, Nakata K

Immunology Letters 212 22 - 29 2019年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1016/j.imlet.2019.05.013

PubMed

researchmap
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative. 査読国際誌

Kawamoto K, Suzuki T, Kasami T, Kiryu M, Sone H, Miyoshi H, Ohshima K, Takizawa J

Hematological oncology 37 ( 2 ) 212 - 214 2019年4月

　詳細を見る

担当区分：最終著者記述言語：英語

DOI： 10.1002/hon.2565

PubMed

researchmap
Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. 査読

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Tamura S, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

Internal medicine (Tokyo, Japan) 58 ( 4 ) 575 - 580 2019年2月

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.2169/internalmedicine.1686-18

PubMed

researchmap
Anaplastic large cell lymphoma, with 1,25(OH)<sub><sup>2</sup></sub>D<sub><sup>3</sup></sub>-mediated hypercalcemia: A case report. 査読

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

Journal of clinical and experimental hematopathology : JCEH 59 ( 1 ) 22 - 28 2019年

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3960/jslrt.18033

PubMed

researchmap
Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. 査読

Tamura S, Kawamoto K, Miyoshi H, Suzuki T, Katagiri T, Kasami T, Nemoto H, Miyakoshi S, Kobayashi H, Shibasaki Y, Masuko M, Takeuchi K, Ohshima K, Sone H, Takizawa J

Journal of clinical and experimental hematopathology : JCEH 58 ( 4 ) 161 - 165 2018年12月

　詳細を見る

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3960/jslrt.18015

PubMed

researchmap
Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. 査読

Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A, Masunari T, Aoki S, Takizawa J, Suzumiya J, Kimura S

International journal of hematology 108 ( 4 ) 416 - 422 2018年10月

　詳細を見る

DOI： 10.1007/s12185-018-2506-3

PubMed

researchmap
A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. 査読国際誌

Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yasuji Kozai, Koji Kato, Masaharu Miyahara, Toshiaki Yujiri, Ilseung Choi, Katsumichi Fujimaki, Tsuyoshi Muta, Masaaki Kume, Sayaka Moriguchi, Shinobu Tamura, Takeharu Kato, Hiroyuki Tagawa, Junya Makiyama, Yuji Kanisawa, Yuya Sasaki, Daisuke Kurita, Kyohei Yamada, Joji Shimono, Hirohito Sone, Jun Takizawa, Masao Seto, Hiroshi Kimura, Koichi Ohshima

Haematologica 103 ( 6 ) 1018 - 1028 2018年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 patients with adult-onset chronic active Epstein-Barr virus infection diagnosed between 2005 and 2015. Adult onset was defined as an estimated age of onset of 15 years or older. To characterize the clinical features of these adults, we compared them to those of 75 pediatric cases (estimated age of onset <15 years). We compared the prognosis of adult-onset chronic active Epstein-Barr virus infection with that of patients with nasal-type (n=37) and non-nasal-type (n=45) extranodal NK/T-cell lymphoma. The median estimated age of onset of these lymphomas was 39 years (range, 16-86 years). Compared to patients with pediatric-onset disease, those in whom the chronic active Epstein-Barr virus infection developed in adulthood had a significantly decreased incidence of fever (P=0.005), but greater frequency of skin lesions (P<0.001). Moreover, hypersensitivity to mosquito bites and the occurrence of hydroa vacciniforme were less frequent in patients with adult-onset disease (P<0.001 and P=0.0238, respectively). Thrombocytopenia, high Epstein-Barr virus nuclear antigen antibody titer, and the presence of hemophagocytic syndrome were associated with a poor prognosis (P=0.0087, P=0.0236, and P=0.0149, respectively). Allogeneic hematopoietic stem cell transplantation may improve survival (P=0.0289). Compared to pediatric-onset chronic active Epstein-Barr virus infection and extranodal NK/T-cell lymphoma, adult-onset chronic active Epstein-Barr virus infection had a poorer prognosis (P<0.001 and P=0.0484, respectively). Chronic active Epstein-Barr virus infection can develop in a wide age range, with clinical differences between adult-onset and pediatric-onset disease. Adult-onset chronic active Epstein-Barr virus infection is a disease with a poor prognosis. Further research will be needed.

DOI： 10.3324/haematol.2017.174177

PubMed

researchmap
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response 査読国際誌

Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K

Leukemia 32 ( 12 ) 2590 - 2603 2018年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1038/s41375-018-0154-5

PubMed

researchmap
Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. 査読国際誌

Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K

Hematol Oncol. 36 ( 3 ) 591 - 599 2018年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1002/hon.2506

PubMed

researchmap
MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia. 査読

Kozakai T, Takahashi M, Higuchi M, Hara T, Saito K, Tanaka Y, Masuko M, Takizawa J, Sone H, Fujii M

International journal of hematology 107 ( 3 ) 337 - 344 2018年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s12185-017-2359-1

PubMed

researchmap
Clinicopathological and genomic analysis of double-hit follicular lymphoma: Comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements 査読

Masashi Miyaoka, Yara Y. Kikuti, Joaquim Carreras, Haruka Ikoma, Shinichiro Hiraiwa, Akifumi Ichiki, Minoru Kojima, Kiyoshi Ando, Tomoyuki Yokose, Rika Sakai, Masahiro Hoshikawa, Naoto Tomita, Ikuo Miura, Katsuyoshi Takata, Tadashi Yoshino, Jun Takizawa, Silvia Bea, Elias Campo, Naoya Nakamura

Modern Pathology 31 ( 2 ) 313 - 326 2018年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nature Publishing Group

DOI： 10.1038/modpathol.2017.134

Scopus

PubMed

researchmap
Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. 査読国際誌

Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa

Hematological oncology 36 ( 1 ) 166 - 173 2018年2月

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma. However, the efficacy of BV toward ENKTL has not yet been established. Therefore, we investigated the expression of CD30 in a large cohort to evaluate BV as a potential treatment for ENKTL. In this study, 97 Japanese patients with newly diagnosed ENKTL between January 2007 and December 2015 were enrolled. Flow cytometry and immunohistochemistry were performed for the evaluation of CD30 expression. If the cut-off value of CD30 expression is 1% or more, there were 55 positive cases (56.5%). According to the localization of lesion, the frequency of CD30 expression was significantly higher in the non-nasal type than in the nasal type (P = .0394). No differences were observed in almost all clinical characteristics between CD30-positive cases and CD30-negative cases. In addition, the expression of CD30 was not a prognostic factor for either overall survival or progression-free survival. In conclusion, frequent expression of CD30 in ENKTL suggests anti-CD30 antibody-based therapy may be an effective treatment.

DOI： 10.1002/hon.2482

PubMed

researchmap
Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome A case report and literature review 査読

Takayuki Katagiri, Takashi Ushiki, Masayoshi Masuko, Tomoyuki Tanaka, Shukuko Miyakoshi, Kyoko Fuse, Yasuhiko Shibasaki, Jun Takizawa, Sadao Aoki, Hirohito Sone

MEDICINE 96 ( 36 ) e7975 2017年9月

　詳細を見る

記述言語：英語

DOI： 10.1097/MD.0000000000007975

Web of Science

PubMed

researchmap
Clinicopathological features of cryptococcal lymphadenitis and a review of literature. 査読

Kawamoto K, Miyoshi H, Suzuki T, Muto R, Yamada K, Yanagida E, Koshino M, Sasaki Y, Takizawa J, Sone H, Sugita Y, Seto M, Ohshima K

Journal of clinical and experimental hematopathology : JCEH 57 ( 1 ) 26 - 30 2017年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3960/jslrt.17011

PubMed

researchmap
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified 査読

Keisuke Kawamoto, Hiroaki Miyoshi, Eriko Yanagida, Noriaki Yoshida, Junichi Kiyasu, Yasuji Kozai, Tatsuma Morikita, Takeharu Kato, Hitoshi Suzushima, Shinobu Tamura, Tsuyoshi Muta, Koji Kato, Tetsuya Eto, Ritsuko Seki, Koji Nagafuji, Hirohito Sone, Jun Takizawa, Masao Seto, Koichi Ohshima

EUROPEAN JOURNAL OF HAEMATOLOGY 98 ( 5 ) 459 - 466 2017年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/ejh.12856

Web of Science

PubMed

researchmap
Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan 査読

Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi, Naoko Asano, Jun Amaki, Takeshi Akiba, Takeshi Maeda, Satoshi Itasaka, Nobuko Kubota, Yoshihiro Saito, Yukio Kobayashi, Jun Itami, Kyoko Ueda, Kana Miyazaki, Noriko Ii, Naoto Tomita, Nodoka Sekiguchi, Jun Takizawa, Bungo Saito, Tohru Murayama, Toshihiko Ando, Hideho Wada, Rie Hyo, Yasuo Ejima, Masatoshi Hasegawa, Naoyuki Katayama

JOURNAL OF CLINICAL ONCOLOGY 35 ( 1 ) 32 - + 2017年1月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1200/JCO.2016.68.1619

Web of Science

PubMed

researchmap
A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma 査読

Katsuhiro Miura, Jun Konishi, Takaaki Miyake, Masanori Makita, Atsuko Hojo, Yasufumi Masaki, Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiya, Koichi Kitazume, Yoshinobu Maeda, Jun Takizawa, Rika Sakai, Tomofumi Yano, Kazuhiko Yamamoto, Kazutaka Sunami, Yasushi Hiramatsu, Kazutoshi Aoyama, Hideki Tsujimura, Jun Murakami, Yoshihiro Hatta, Masatoshi Kanno

ONCOLOGIST 22 ( 5 ) 554 - 560 2017年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1634/theoncologist.2016-0260

Web of Science

PubMed

researchmap
Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy. 査読

Suwabe T, Shibasaki Y, Kaihatsu A, Katagiri T, Miyakoshi S, Fuse K, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

[Rinsho ketsueki] The Japanese journal of clinical hematology 58 ( 1 ) 32 - 36 2017年

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）

DOI： 10.11406/rinketsu.58.32

PubMed

researchmap
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma 査読

Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa

LEUKEMIA & LYMPHOMA 57 ( 12 ) 2763 - 2770 2016年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1080/10428194.2016.1195498

Web of Science

PubMed

researchmap
Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients 査読

Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Jun Takizawa, Hirohito Sone, Koichi Ohshima

AMERICAN JOURNAL OF SURGICAL PATHOLOGY 40 ( 11 ) 1473 - 1483 2016年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1097/PAS.0000000000000727

Web of Science

PubMed

researchmap
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma 査読

Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Naoya Nakamura, Koichi Ohshima, Hirohito Sone, Jun Takizawa

CANCER SCIENCE 107 ( 6 ) 853 - 861 2016年6月

　詳細を見る

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/cas.12942

Web of Science

PubMed

researchmap
Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan. 査読

Yamaguchi Motoko, Suzuki Ritsuro, Oguchi Masahiko, Asano Naoko, Amaki Jun, Maeda Takeshi, Kubota Nobuko, Kobayashi Yukio, Ueda Kyoko, Miyazaki Kana, Tomita Naoto, Sekiguchi Nodoka, Takizawa Jun, Saito Bungo, Murayama Tohru, Ando Toshihiko, Wada Hideho, Hyo Rie, Hasegawa Masatoshi, Katayama Naoyuki

JOURNAL OF CLINICAL ONCOLOGY 34 ( 15 ) 2016年5月

　詳細を見る

DOI： 10.1200/JCO.2016.34.15_suppl.7541

Web of Science

researchmap
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma 査読

T. Aoki, K. Shimada, R. Suzuki, K. Izutsu, A. Tomita, Y. Maeda, J. Takizawa, K. Mitani, T. Igarashi, K. Sakai, K. Miyazaki, K. Mihara, K. Ohmachi, N. Nakamura, H. Takasaki, H. Kiyoi, S. Nakamura, T. Kinoshita, M. Ogura

BLOOD CANCER JOURNAL 5 2015年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1038/bcj.2015.101

Web of Science

PubMed

researchmap
Fatal tracheal aspergillosis during rituximab combined chemotherapy for diffuse large B-cell lymphoma that developed after lung transplantation 査読

K. Kawamoto, Y. Shibasaki, S. Sato, H. Nemoto, J. Takizawa, M. Narita, M. Tsuchida, H. Sone, M. Masuko

TRANSPLANT INFECTIOUS DISEASE 17 ( 6 ) 872 - 875 2015年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/tid.12458

Web of Science

PubMed

researchmap
Possible Involvement of Lung Cells Harboring an Abnormal Karyotype in the Pathogenesis of Pulmonary Alveolar Proteinosis Associated with Myelodysplastic Syndrome.

Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, Takizawa J, Sone H, Tazawa R, Saijo Y, Ishii H, Nakata K

Ann Am Thorac Soc 12 ( 8 ) 1251 - 1253 2015年8月

　詳細を見る

DOI： 10.1513/AnnalsATS.201503-175LE

researchmap
The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients. 査読国際誌

Shibasaki Y, Seki Y, Tanaka T, Miyakoshi S, Fuse K, Kozakai T, Kobayashi H, Ushiki T, Abe T, Yano T, Moriyama M, Kuroha T, Isahai N, Takizawa J, Narita M, Koyama S, Furukawa T, Sone H, Masuko M

Leukemia research 39 ( 6 ) 667 - 671 2015年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1016/j.leukres.2015.03.021

PubMed

researchmap
Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia. 査読

Fuse K, Matsuyama Y, Moriyama M, Miyakoshi S, Shibasaki Y, Takizawa J, Furukawa T, Fuse I, Matsumura H, Uchida S, Takahashi Y, Kamimura K, Abe H, Suda T, Aoyagi Y, Sone H, Masuko M

Internal medicine (Tokyo, Japan) 54 ( 6 ) 657 - 661 2015年

　詳細を見る

DOI： 10.2169/internalmedicine.54.2332

PubMed

researchmap
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan 査読

Tomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, Chiaki Nakaseko, Hiroshi Arima, Kazuyuki Shimada, Akihiro Tomita, Makoto Sasaki, Jun Takizawa, Kinuko Mitani, Tadahiko Igarashi, Yoshinobu Maeda, Noriko Fukuhara, Fumihiro Ishida, Nozomi Niitsu, Ken Ohmachi, Hirotaka Takasaki, Naoya Nakamura, Tomohiro Kinoshita, Shigeo Nakamura, Michinori Ogura

HAEMATOLOGICA 99 ( 12 ) 1817 - 1825 2014年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3324/haematol.2014.111203

Web of Science

PubMed

researchmap
Activation of the Leukemia Plasmacytoid Dendritic Cell Line PMDC05 by Toho-1, a Novel IDO Inhibitor 査読

Akie Yamahira, Miwako Narita, Minami Iwabuchi, Takayoshi Uchiyama, Shunpei Iwaya, Rie Ohiwa, Yoshinori Nishizawa, Takafumi Suzuki, Yusaku Yokoyama, Shigeo Hashimoto, Jun Takizawa, Hirohito Sone, Masuhiro Takahashi

ANTICANCER RESEARCH 34 ( 8 ) 4021 - 4028 2014年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Web of Science

PubMed

researchmap
Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways 査読

Harumi Kato, Kennosuke Karube, Kazuhito Yamamoto, Jun Takizawa, Shinobu Tsuzuki, Yasushi Yatabe, Teru Kanda, Miyuki Katayama, Yukiyasu Ozawa, Kenji Ishitsuka, Masataka Okamoto, Tomohiro Kinoshita, Koichi Ohshima, Shigeo Nakamura, Yasuo Morishima, Masao Seto

CANCER SCIENCE 105 ( 5 ) 537 - 544 2014年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/cas.12389

Web of Science

researchmap
Early Diagnosis of Hepatic Intravascular Lymphoma: A Case Report and Literature Review 査読

Hiroyuki Abe, Kenya Kamimura, Maiko Mamizu, Yasuhiko Shibazaki, Takanobu Ishiguro, Shin-ichi Katada, Yu-ki Nishiyama, Yoshifumi Takahashi, Yu-ya Hatano, Ken-ichi Mizuno, Yukari Watanabe, Aiko Nagashima, Jun Takizawa, Manabu Takeuchi, Hirokazu Kawai, Minoru Nomoto, Hirohito Sone, Masatoyo Nishizawa, Yutaka Aoyagi

INTERNAL MEDICINE 53 ( 6 ) 587 - 593 2014年

　詳細を見る

記述言語：英語

DOI： 10.2169/internalmedicine.53.1812

Web of Science

PubMed

researchmap
Manifestations of Fulminant CD8 T-cell Post-transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation 査読

Tomoyuki Tanaka, Jun Takizawa, Shukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Koichi Ohshima, Ken Toba, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

INTERNAL MEDICINE 53 ( 18 ) 2115 - 2119 2014年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.2169/internalmedicine.53.2384

Web of Science

PubMed

researchmap
Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine. 査読

Okazuka K, Masuko M, Matsuo Y, Miyakoshi S, Tanaka T, Kozakai T, Kobayashi H, Fuse K, Shibasaki Y, Moriyama M, Takizawa J, Fuse I, Toba K, Furukawa T

Intern Med 52 ( 11 ) 1239 - 1242 2013年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：The Japanese Society of Internal Medicine

A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP.<br>

DOI： 10.2169/internalmedicine.52.0080

CiNii Article

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2014315593
MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: Multicenter analysis of Japanese patients with diffuse large B-cell lymphoma 査読

Minoru Kojima, Hidekazu Nishikii, Jun Takizawa, Sadao Aoki, Masayuki Noguchi, Shigeru Chiba, Kiyoshi Ando, Naoya Nakamura

Leukemia and Lymphoma 54 ( 10 ) 2149 - 2154 2013年10月

　詳細を見る

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3109/10428194.2013.771398

Scopus

PubMed

researchmap
Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma. 査読国際誌

Ogura R, Aoki H, Natsumeda M, Shimizu H, Kobayashi T, Saito T, Takizawa J, Okamoto K, Hasegawa G, Umezu H, Ohshima K, Takahashi H, Fujii Y, Kakita A

Neuropathology : official journal of the Japanese Society of Neuropathology 33 ( 4 ) 436 - 441 2013年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/neup.12005

PubMed

researchmap
Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type 査読

Yoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda, Chizuko Hashimoto, Fumihiro Ishida, Koji Izutsu, Noriyasu Fukushima, Yasushi Isobe, Jun Takizawa, Yuichi Hasegawa, Hajime Kobayashi, Seiichi Okamura, Hikaru Kobayashi, Motoko Yamaguchi, Junji Suzumiya, Rie Hyo, Shigeo Nakamura, Keisei Kawa, Kazuo Oshimi, Ritsuro Suzuki

CLINICAL CANCER RESEARCH 18 ( 15 ) 4183 - 4190 2012年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1158/1078-0432.CCR-12-1064

Web of Science

researchmap
IgM-type GM-CSF autoantibody is etiologically a bystander but associated with IgG-type autoantibody production in autoimmune pulmonary alveolar proteinosis 査読

Takahito Nei, Shinya Urano, Natsuki Motoi, Jun Takizawa, Chinatsu Kaneko, Hiroko Kanazawa, Ryushi Tazawa, Kazuhide Nakagaki, Kiyoko S. Akagawa, Keiichi Akasaka, Toshio Ichiwata, Arata Azuma, Koh Nakata

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 302 ( 9 ) L959 - L964 2012年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1152/ajplung.00378.2011

Web of Science

researchmap
Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan 査読

Katsuhiro Miura, Hirotaka Takasaki, Hideki Tsujimura, Masatoshi Kanno, Yoshinobu Maeda, Naoto Tomita, Kazue Takai, Yasufumi Masaki, Jun Takizawa, Hiraku Mori, Yasushi Terasaki, Takashi Yoshida, Jin Takeuchi, Shigeki Motomura

INTERNATIONAL JOURNAL OF HEMATOLOGY 93 ( 5 ) 684 - 686 2011年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s12185-011-0845-4

Web of Science

researchmap
Multifocal mucosa-associated lymphoid tissue lymphoma associated with IgG4-related disease: a case report 査読

Tokuhide Oyama, Jun Takizawa, Naoya Nakamura, Sadao Aoki, Yoshifusa Aizawa, Haruki Abe

JAPANESE JOURNAL OF OPHTHALMOLOGY 55 ( 3 ) 304 - 306 2011年5月

　詳細を見る

記述言語：英語

DOI： 10.1007/s10384-011-0003-9

Web of Science

PubMed

researchmap
Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis 査読

Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, Shigeru Kusumoto, Masataka Okamoto, Masahiro Yokoyama, Yasushi Takamatsu, Kazutaka Sunami, Akira Miyata, Kayoko Murayama, Akira Sakai, Morio Matsumoto, Katsuji Shinagawa, Akinobu Takaki, Keitaro Matsuo, Tomohiro Kinoshita, Mitsune Tanimoto

BLOOD 116 ( 24 ) 5119 - 5125 2010年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1182/blood-2010-06-289231

Web of Science

researchmap
Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single timepoint for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation. 査読

Furukawa T, Kurasaki-Ida T, Masuko M, Tsukada N, Okazuka K, Sato N, Yano T, Abe T, Momoi A, Shibasaki Y, Higashimura M, Karimata K, Moriyama M, Kuroha T, Takizawa J, Toba K, Narita M, Fuse I, Takahashi M, Aizawa Y

Int J Hematol. 92 ( 1 ) 144 - 151 2010年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s12185-010-0610-0

CiNii Article

CiNii Books

researchmap
Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system - Laboratory investigation 査読

Jie Li, Hiroaki Okamoto, Chunyue Yin, Jay Jagannathan, Jun Takizawa, Sadao Aoki, Sven Glaesker, Elisabeth J. Rushing, Alexander O. Vortmeyer, Edward H. Oldfield, Ryuya Yamanaka, Zhengping Zhuang

JOURNAL OF NEUROSURGERY 109 ( 3 ) 536 - 546 2008年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.3171/JNS/2008/109/9/0536

Web of Science

researchmap
Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma 査読

Anri Saitoh, Miwako Narita, Norihiro Watanabe, Nozomi Tochiki, Noriyuki Satoh, Jun Takizawa, Tatsuo Furukawa, Ken Toba, Yoshifusa Aizawa, Shohji Shinada, Masuhiro Takahashi

MEDICAL ONCOLOGY 25 ( 2 ) 137 - 147 2008年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s12032-007-9004-4

Web of Science

researchmap
Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation 査読

Jun Takizawa, Sadao Aoki, Tori Kurasaki, Masutaka Higashimura, Keiichiro Honma, Toshiki Kitajima, Akihito Momoi, Hidenobu Takahashi, Naoya Nakamura, Tatsuo Furukawa, Yoshifusa Aizawal

AMERICAN JOURNAL OF HEMATOLOGY 82 ( 12 ) 1113 - 1115 2007年12月

　詳細を見る

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1002/ajh.21042

Web of Science

PubMed

researchmap
Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. 査読

Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M

J Clin Exp Hematop. 47 ( 2 ) 61 - 72 2007年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：The Japanese Society for Lymphoreticular Tissue Research

In order to establish the method of generating powerful γδ T cells for anti-tumor immunotherapy, we investigated the effects of monocyte-derived dendritic cells (mo-DCs) on anti-tumor cytotoxicity of expanded γδ T cells. Activation of γδ T cells co-cultured for 2-3 days with immature or mature mo-DCs was evaluated by CD69 expression and anti-tumor cytotoxicity using two assays : the 5- (and 6-) carboxyfluorescein diacetate, succinimidyl ester-based cytotoxicity assay and the calcein-AM-based Terascan assay. γδ T cells were used as effector cells and myeloma cell line (RPMI8226) or chronic myelogenous leukemia blastic crisis cell line (C2F8) were used as target cells. CD69 expression on γδ T cells was enhanced by co-culture with both immature and mature mo-DCs in a cell-number-dependent fashion. CD69 expression was enhanced after addition of mo-DCs of either autologous or allogeneic origin. Activation of γδ T cells with mo-DCs enhanced anti-tumor cytotoxicity of γδ T cells against RPMI8226 and C2F8 in an effector-to-target ratio-dependent manner. Activation of γδ T cells by mo-DCs was associated with the enhancement of anti-tumor cytotoxicity of γδ T cells. Potent γδ T cells activated by mo-DCs were considered to be applicable to an efficient γδ T cell-mediated immunotherapy for tumors. [<I>J Clin Exp Hematopathol 47(2) </I><I>: 61</I>-<I>72, 2007</I>]

DOI： 10.3960/jslrt.47.61

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2008186007
Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients 査読

Hidenobu Takahashi, Tatsuo Furukawa, Toshio Yano, Naoko Sato, Jun Takizawa, Tori Kurasaki, Takashi Abe, Miwako Narita, Masayoshi Masuko, Satoru Koyama, Ken Toba, Masuhiro Takahashi, Yoshifusa Aizawa

EXPERIMENTAL HEMATOLOGY 35 ( 7 ) 1091 - 1099 2007年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1016/j.exphem.2007.03.015

Web of Science

researchmap
Plasma brain natriuretic peptide during myeloablative stem cell transplantation. 査読

Masuko M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K, Aoki S, Fuse I, Kodama M, Furukawa T, Aizawa Y

Internal medicine (Tokyo, Japan) 46 ( 9 ) 551 - 555 2007年

　詳細を見る

記述言語：英語出版者・発行元：The Japanese Society of Internal Medicine

<b>Objective:</b> Cardiovascular complication is one of the serious complications in stem cell transplantation (SCT). We measured plasma brain natriuretic peptide (BNP) concentrations in patients who received SCT to evaluate possible cardiac toxicity of the regimens employed in SCT.<br> <b>Patients:</b> Ten patients with allogeneic SCT and 5 patients with autologous SCT using myeloablative conditioning regimens were enrolled. The preparative chemotherapy for 8 patients with allogeneic SCT included cyclophosphamide (60 mg/kg i.v. for 2 days) and other drugs and that for autologous SCT included cyclophosphamide (50 mg/kg for 2 days) and other drugs. Total body irradiation (TBI) was employed only in the patients who received allogeneic SCT.<br> <b>Method:</b> Plasma BNP was measured using a radioimmunoassay for human BNP before and after SCT.<br> <b>Results:</b> In 13 of 15 patients, BNP levels were elevated after SCT. In patients who received a total body irradiation (TBI) of 13.2 Gy, BNP levels were higher than those without irradiation (p=0.01). The BNP level reached a peak within 6 months after SCT in most patients and fell thereafter. But 7 of the 15 patients (46.7%) had an abnormally high level of plasma BNP even after 6 months of SCT which suggests subclinical myocardial damage.<br> <b>Conclusion:</b> A rise in plasma BNP was frequently observed after SCT, and may be considered to represent cardiac damage caused by the preparative chemotherapy and/or total body irradiation. Since a rise was noted 6 months after SCT, long-term evaluation of cardiac function is important.<br>

DOI： 10.2169/internalmedicine.46.6188

PubMed

CiNii Article

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2007315596
Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody 査読

N Nakamura, H Hase, D Sakurai, S Yoshida, M Abe, N Tsukada, J Takizawa, S Aoki, M Kojima, S Nakamura, T Kobata

VIRCHOWS ARCHIV 447 ( 1 ) 53 - 60 2005年7月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1007/s00428-005-1275-6

Web of Science

researchmap
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy 査読

G Hatzivassiliou, Miller, I, J Takizawa, N Palanisamy, PH Rao, S Iida, S Tagawa, M Taniwaki, J Russo, A Neri, G Cattoretti, R Clynes, C Mendelsohn, RSK Chaganti, R Dalla-Favera

IMMUNITY 14 ( 3 ) 277 - 289 2001年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1016/S1074-7613(01)00109-1

Web of Science

PubMed

researchmap
5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: A case report 査読

Hidenobu Takahashi, Tatsuo Furukawa, Shigeo Hashimoto, Naoko Kanazawa, Naoaki Satoh, Noriatsu Suzuki, Jun Takizawa, Yumiko Uesugi, Masuhiro Takahashi, Yoshifusa Aizawa, Tadashi Koike

American Journal of Hematology 64 ( 2 ) 120 - 123 2000年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1002/(SICI)1096-8652(200006)64:2<120::AID-AJH9>3.0.CO;2-M

Scopus

PubMed

researchmap
The TCL1 oncogene is not overexpressed in patients with adult T cell leukemia 査読

J Takizawa, M Seto

LEUKEMIA 13 ( 2 ) 314 - 314 1999年2月

　詳細を見る

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1038/sj.leu.2401267

Web of Science

PubMed

researchmap
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia 査読

J Takizawa, R Suzuki, H Kuroda, A Utsunomiya, Y Kagami, T Joh, Y Aizawa, R Ueda, M Seto

JAPANESE JOURNAL OF CANCER RESEARCH 89 ( 7 ) 712 - 718 1998年7月

　詳細を見る

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/j.1349-7006.1998.tb03275.x

Web of Science

PubMed

researchmap
Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation 査読

Tatsuroh Joh, Yoshitoyo Kagami, Kazuhito Yamamoto, Tatsuya Segawa, Jun Takizawa, Toshitada Takahashi, Ryuzo Ueda, Masao Seto

Oncogene 13 ( 9 ) 1945 - 1953 1996年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Scopus

PubMed

researchmap
Fanconi貧血と思われる再生不良性貧血に続発した急性骨髄性白血病に親子間同種骨髄移植を施行した1症例査読

瀧澤淳, 岸賢治, 森山美昭, 橋本誠雄, 後藤隆夫, 樋口渉, 和田研, 成田美和子, 青木定夫, 高橋益広, 小池正, 柴田昭

臨床血液 36 ( 6 ) 615 - 620 1995年6月

　詳細を見る

担当区分：筆頭著者,　責任著者記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本血液学会

症例は19歳，男性。生後1カ月より貧血を指摘され，低身長，右母指形成不全，皮膚色素沈着，精神発達遅延など多発奇形を合併しており，Fanconi貧血(FA)が疑われ経過観察されてきた。1993年1月より，汎血球減少が著明となり，頻回の輸血が必要となったため，8月31日当科入院となった。入院時骨髄穿刺では，骨髄は有核細胞数1.1×10<sup>4</sup>/μ<i>l</i>と低形成であったが，芽球42.0%, 前骨髄球9.6%を認め，AML (M2)へ移行したものと判断した。少量Ara-C療法で寛解は得られず，HLA完全一致，MLC陰性の父親をdonorとして，10月15日同種骨髄移植を施行した。移植前処置はcyclophosphamideを用いず，Ara-Cとetoposideの大量投与とTBI (12Gy)を併用したが，重篤なregimen related toxicityは認めず，骨髄生着が得られた。急性GVHD予防はciclosporin Aとmethotrexateを用い，GVHDは認められなかった。白血病に移行したFAに対するBMT成功例は少なく，文献的考察を含め報告する。

DOI： 10.11406/rinketsu.36.615

CiNii Article

CiNii Books

researchmap
Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma 査読

Yuma Nato, Kana Miyazaki, Dai Maruyama, Hiroyuki Takahashi, Kazutaka Sunami, Eiju Negoro, Satsuki Murakami, Takahiro Okada, Nobuyuki Takayama, Yuri Miyazawa, Ilseung Choi, Shuji Momose, Yuto Kaneda, Masahiro Yoshida, Naoto Tomita, Tohru Murayama, Momoko Nishikori, Junji Hiraga, Kohtaro Toyama, Naoki Takahashi, Taro Masunari, Jun Takizawa, Isao Tawara, Naoko Asano, Koichi Ohshima, Koji Izutsu, Koji Kato, Ritsuro Suzuki, Motoko Yamaguchi

Annals of Hematology 105 ( 5 ) 2026年4月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

DOI： 10.1007/s00277-026-07021-0

researchmap

その他リンク： https://link.springer.com/article/10.1007/s00277-026-07021-0
Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study 査読

Masaki Mitobe, Satoshi Shibuma, Haruhiko Takahashi, Jotaro On, Toru Takino, Keita Kawabe, Yoshihiro Mouri, Shunsuke Kumagai, Takashi Kozakai, Akihito Momoi, Naomi Suzuki, Takao Fukushima, Takaharu Suzuki, Hiroyuki Kuroda, Etsuji Saji, Kimihiko Nakamura, Hideki Hashidate, Asa Nakahara, Takahiro Tomita, Jun Watanabe, Yoshihiro Tsukamoto, Masayasu Okada, Tetsuya Hiraishi, Shinya Yamashita, Takuya Akai, Satoshi Kuroda, Akiyoshi Kakita, Hirohito Sone, Jun Takizawa, Makoto Oishi, Manabu Natsumeda

Neuro-Oncology Advances 8 ( 1 ) 2026年1月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press (OUP)

Abstract

Background

The gold standard for the diagnosis of primary central nervous system lymphoma (PCNSL) remains surgical biopsy, but it carries the risk of complications, and operability depends on the size and location of the lesion or the patient’s condition. Previously, we have reported the reliable detection of MYD88 L265P-mutant droplets in cerebrospinal fluid (CSF) cell-free DNA (cfDNA) of PCNSL using droplet digital PCR (ddPCR). In the present study, we conducted a multi-institutional study to diagnose and initiate treatment for PCNSL by liquid biopsy alone without a surgical biopsy.

Methods

We analyzed 10 patients from 5 institutions who were deemed difficult to biopsy surgically and were subsequently treated based on the detection of MYD88 L265P-mutant droplets in their CSF cfDNA. CSF was obtained by lumbar puncture at each institution, cfDNA was extracted at Niigata University, and ddPCR was performed to detect MYD88 L265P-mutant droplets.

Results

Surgical biopsy was not performed in 8 patients because the lesions were located in deep locations, such as the brainstem, and in 2 patients because of low performance status and/or advanced age. MYD88 L265P-mutant droplets were detected in all cases. Treatment response was observed in all cases. In a patient with chronic renal failure, liquid biopsy was helpful to rule out possible relapse.

Conclusions

Liquid biopsy for the diagnosis of PCNSL has the potential to replace surgical biopsy with a less-invasive method and early diagnosis, leading to early treatment and possibly better outcomes. Further large-scale studies are warranted to establish the reliability of this approach.

DOI： 10.1093/noajnl/vdaf274

researchmap

その他リンク： https://academic.oup.com/noa/article-pdf/8/1/vdaf274/68133060/vdaf274.pdf
Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Yuri Furuyama, Tatsuya Suwabe, Ayako Kawakami, Hodaka Yonezawa, Takayuki Katagiri, Kyoko Fuse, Yasuhiko Shibasaki, Takashi Ushiki, Jun Takizawa, Hirohito Sone, Masayoshi Masuko

Cureus 2025年7月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

DOI： 10.7759/cureus.87084

researchmap
肺がんに対する免疫チェックポイント阻害薬併用化学療法後に発症した血管免疫芽球性T細胞リンパ腫

川上絢子, 黒田裕行, 鈴木隆晴, 小林弘典, 阿部静太郎, 宇井雅博, 井上佳菜子, 大島孝一, 曽根博仁, 瀧澤淳

臨床血液 63 ( 7 ) 759 - 763 2022年7月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本血液学会-東京事務局

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J01540&link_issn=&doc_id=20220804290007&doc_link_id=1390011483838490240&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390011483838490240&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif
[Angioimmunoblastic T-cell lymphoma after immune checkpoint inhibitor-combined chemotherapy for lung cancer].

Ayako Kawakami, Hiroyuki Kuroda, Takaharu Suzuki, Hironori Kobayashi, Seitaro Abe, Masahiro Ui, Kanako Inoue, Koichi Oshima, Hirohito Sone, Jun Takizawa

[Rinsho ketsueki] The Japanese journal of clinical hematology 63 ( 7 ) 759 - 763 2022年

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）

A 68-year-old male patient with lung adenocarcinoma, who was treated with chemotherapy and immune checkpoint inhibitors (ICIs), developed lymphadenopathy during treatment. His para-aortic lymph nodes increased to 2.0 cm in diameter. Both inguinal lymph nodes were 1.5 cm in diameter, and multiple hepatic masses appeared. After the ICI readministration, both inguinal lymph nodes increased to 2.0 cm in diameter, but the para-aortic lymph nodes and hepatic masses remained. Angioimmunoblastic T-cell lymphoma (AITL) diagnosis was established after the right inguinal lymph node biopsy, which was accompanied by an infiltration of Epstein-Barr virus (EBV)-encoded small ribonucleic acid-positive B-cells. After the ICI discontinuation, the inguinal lymph nodes decreased to 1.5 cm in diameter, but the para-aortic lymph nodes remained, and hepatic masses increased. Hepatic lesions were possibly lung cancer metastasis. The ICI administration and EBV reactivation were potentially associated with AITL development in the present case. The natural shrinkage of lymphoma after the ICI cessation implied the immunological mechanism like that of the methotrexate-related lymphoproliferative disease.

DOI： 10.11406/rinketsu.63.759

PubMed

researchmap
Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. 査読

Suzuki T, Kawamoto K, Tamura S, Uemura S, Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y, Moriyama M, Masuko M, Narita M, Sone H, Aoki S, Nakamura N, Oshima K, Takizawa J

[Rinsho ketsueki] The Japanese journal of clinical hematology 58 ( 8 ) 905 - 911 2017年

　詳細を見る

担当区分：最終著者,　責任著者記述言語：日本語掲載種別：研究論文（学術雑誌）

DOI： 10.11406/rinketsu.58.905

PubMed

researchmap
[Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity]. 査読

Tanaka T, Kozakai T, Kitajima T, Fuse K, Kobayashi H, Ushiki T, Shibazaki Y, Moriyama M, Takizawa J, Sone H, Fuse I, Masuko M

[Rinsho ketsueki] The Japanese journal of clinical hematology 58 ( 12 ) 2402 - 2405 2017年

　詳細を見る

記述言語：日本語出版者・発行元：一般社団法人日本血液学会

<p>症例は75歳の女性。血液検査で貧血と末梢血に芽球を認められたため，当院を紹介受診した。骨髄穿刺で骨髄異形成症候群（myelodysplastic syndrome with excess blasts 2, MDS-EB-2）と診断された。血球減少の進行や芽球の増加，および出血症状はなく経過していた。診断から10ヶ月後，左手母指球に外傷を負い，内出血が持続し，止血困難となったため緊急入院した。血小板数は正常範囲であったが，血小板機能検査でコラーゲン凝集能とアラキドン酸凝集能の低下を認められた。抗血小板薬の内服はなく，またこれまで出血傾向の既往もなかったことから，MDSによる2次性の血小板機能低下による出血と判断し，血小板輸血を行い止血した。MDSの患者では，潜在的に血小板凝集能が低下していることが多く，血小板数の割に出血傾向が強い場合には血小板凝集能を調べ，血小板輸血などの治療介入を検討する必要がある。</p>

DOI： 10.11406/rinketsu.58.2402

PubMed

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2018121562

▶ 全件表示

書籍等出版物

今日の治療指針

福井, 次矢, 高木, 誠, 小室, 一成, 阿部, 理一郎（担当：分担執筆 , 範囲: 慢性リンパ性白血病）

医学書院 2026年1月（ ISBN:9784260062480 ）

　詳細を見る

総ページ数：59, 2226p 記述言語：日本語

CiNii Books

researchmap
EBM血液疾患の治療

金倉, 譲, 木崎, 昌弘, 鈴木, 律朗, 神田, 善伸, 大森, 司, 山崎, 宏人（担当：分担執筆 , 範囲: 再発・難治性CLLの治療方針）

中外医学社 2024年10月（ ISBN:9784498225480 ）

　詳細を見る

総ページ数：v, 567p 記述言語：日本語

CiNii Books

researchmap

その他リンク： https://webview.isho.jp/book/detail/abs/10.18886/9784498225480
新臨床腫瘍学

日本臨床腫瘍学会（担当：分担執筆 , 範囲: 51 造血・リンパ組織の腫瘍 2) 白血病 D. 慢性リンパ性白血病（CLL）と類縁疾患）

南江堂 2024年2月（ ISBN:9784524204267 ）

　詳細を見る

総ページ数：xx, 767p 記述言語：日本語

CiNii Books

researchmap
血液専門医テキスト = Textbook of Hematology

日本血液学会（担当：分担執筆 , 範囲: 慢性リンパ性白血病とその類縁疾患）

南江堂 2023年10月（ ISBN:9784524203710 ）

　詳細を見る

総ページ数：xxii, 632p 記述言語：日本語

CiNii Books

researchmap
血液専門医テキスト = Textbook of Hematology

日本血液学会（担当：分担執筆 , 範囲: リンパ腫の病期診断・治療効果判定[FDG-PET（PET-CT）を含む]）

南江堂 2023年10月（ ISBN:9784524203710 ）

　詳細を見る

総ページ数：xxii, 632p 記述言語：日本語

CiNii Books

researchmap
新臨床腫瘍学 : がん薬物療法専門医のために

日本臨床腫瘍学会（担当：分担執筆 , 範囲: 43 造血・リンパ組織の腫瘍 5. 慢性リンパ性白血病（CLL）と類縁疾患）

南江堂 2021年5月（ ISBN:9784524227396 ）

　詳細を見る

総ページ数：xix, 757p 記述言語：日本語

CiNii Books

researchmap
悪性リンパ腫治療マニュアル

永井, 宏和, 山口, 素子, 丸山, 大, 飛内, 賢正, 木下, 朝博, 塚崎, 邦弘（担当：分担執筆 , 範囲: 第Ⅲ章悪性リンパ腫-治療の実際 1. 病型別治療方針 C. 慢性リンパ性白血病/小リンパ球性リンパ腫）

南江堂 2020年11月（ ISBN:9784524226450 ）

　詳細を見る

総ページ数：x, 395p 記述言語：日本語

CiNii Books

researchmap
今日の治療指針 2020年版 : 私はこう治療している

福井次矢, 高木誠, 小室一成（担当：分担執筆 , 範囲: 慢性リンパ性白血病）

医学書院 2020年1月

　詳細を見る

総ページ数：冊記述言語：日本語

researchmap
血液専門医テキスト

日本血液学会（担当：分担執筆 , 範囲: 第Ⅸ章白血球系疾患：腫瘍性疾患 15.慢性リンパ性白血病とその類縁疾患）

南江堂 2019年10月（ ISBN:9784524248827 ）

　詳細を見る

総ページ数：xix, 635p 記述言語：日本語

CiNii Books

researchmap
Molecular Targeted Therapy for DLBCL. Primary Central Nervous System Lymphoma (PCNSL)

Kawamoto K, Takizawa J（担当：分担執筆 , 範囲: Molecular Targeted Therapy for DLBCL.）

Nova science publishers 2016年7月（ ISBN:9781634853224 ）

　詳細を見る

担当ページ：189-200 記述言語：英語著書種別：学術書

researchmap
危機管理について大学病院などの再生医療を支える細胞プロセッシング室運営マニュアル

瀧澤淳（担当：単著）

ウイネット出版/星雲社 2012年

　詳細を見る

記述言語：日本語著書種別：学術書

researchmap
EBM血液疾患の治療

木崎, 昌弘, 鈴木, 律朗, 神田, 善伸, 大森, 司, 山崎, 宏人, 金倉, 譲（担当：分担執筆 , 範囲: 再発・難治末梢性T細胞リンパ腫の治療方針）

中外医学社 2022年10月（ ISBN:9784498225404 ）

　詳細を見る

総ページ数：v, 572p 記述言語：日本語

CiNii Books

researchmap

その他リンク： https://webview.isho.jp/book/detail/abs/10.18886/9784498225404
既治療のハイリスク染色体を有するCLLに対するacalabrutinibとibrutinibのランダム化第Ⅲ相試験（ELEVATE-RR）.

瀧澤淳

科学評論社 2022年6月

　詳細を見る

researchmap
特集慢性白血病-最新の診断と治療- Ⅳ. 慢性白血病の予後予測因子.慢性リンパ性白血病とその類縁疾患の予後予測因子.

瀧澤淳

2021年11月

　詳細を見る

researchmap
EBM血液疾患の治療2021-2022

木崎, 昌弘, 鈴木, 律朗, 神田, 善伸, 大森, 司, 金倉, 譲, 山﨑, 宏人（担当：分担執筆 , 範囲: 再発・再燃びまん性大細胞型B細胞リンパ腫（DLBCL）の治療方針）

中外医学社 2021年1月（ ISBN:9784498225244 ）

　詳細を見る

総ページ数：iv, 637p 記述言語：日本語

CiNii Books

researchmap
今日の治療指針 2021年版 : 私はこう治療している

福井, 次矢, 高木, 誠, 小室, 一成, 赤司, 浩一(大学教員)（担当：分担執筆 , 範囲: 顆粒球減少症（無顆粒球症））

医学書院 2021年1月（ ISBN:9784260042833 ）

　詳細を見る

総ページ数：59, 2151p 記述言語：日本語

CiNii Books

researchmap
造血器腫瘍学(第2 版) 基礎と臨床の最新研究動向

瀧澤淳（担当：分担執筆 , 範囲: V．リンパ系腫瘍の臨床慢性リンパ性白血病および類縁疾患の病因・病態と治療）

日本臨牀社 2020年8月

　詳細を見る

researchmap
EBM血液疾患の治療2019-2020

金倉, 譲, 木崎, 昌弘, 鈴木, 律朗, 神田, 善伸（担当：分担執筆 , 範囲: 若年者マントル細胞リンパ腫の治療方針）

中外医学社 2018年10月（ ISBN:4498125126 ）

　詳細を見る

総ページ数：冊記述言語：日本語

CiNii Books

researchmap
節外性NK/T細胞リンパ腫の治療 EBM 血液疾患の治療2017-2018

瀧澤淳（担当：分担執筆 , 範囲: 節外性NK/T細胞リンパ腫の治療）

中外医学社 2016年10月（ ISBN:9784498225022 ）

　詳細を見る

担当ページ：291-297 記述言語：日本語著書種別：学術書

researchmap
血液疾患の新規治療薬2016 イブルチニブ

瀧澤淳（担当：分担執筆 , 範囲: イブルチニブ）

毘沙門堂 2016年9月（ ISBN:9784907524067 ）

　詳細を見る

総ページ数：56 担当ページ：8-10 記述言語：日本語著書種別：学術書

researchmap
眼・眼付属器リンパ腫節外リンパ腫の臓器別特徴と治療リンパ腫学-最新の研究動向-

瀧澤淳, 尾山徳秀（担当：分担執筆 , 範囲: 節外リンパ腫の臓器別特徴と治療眼・眼付属器リンパ腫）

日本臨牀社 2015年10月

　詳細を見る

総ページ数：695 担当ページ：614-618 記述言語：日本語著書種別：学術書

researchmap
初発CLLの治療方針 EBM 血液疾患の治療2015-2016

瀧澤淳（担当：単著）

中外医学社 2014年

　詳細を見る

記述言語：日本語著書種別：学術書

researchmap
慢性リンパ性白血病今日の治療指針2013年版

瀧澤淳（担当：単著）

医学書院 2013年

　詳細を見る

記述言語：日本語著書種別：学術書

researchmap
慢性関節リウマチに対するTNF阻害剤はリンパ腫の発症リスクを高めるか？ EBM 血液疾患の治療

瀧澤淳（担当：単著）

中外医学社 2012年

　詳細を見る

記述言語：日本語著書種別：学術書

researchmap
Burkittリンパ腫とびまん性大細胞型B細胞リンパ腫の鑑別方法とその治療臨床症例検討を通して学ぶ悪性リンパ腫診療の実際-リンフォーマ井戸端会議から学んだこと-

瀧澤淳, 青木定夫（担当：共著）

メディカルレビュー社 2010年

　詳細を見る

記述言語：日本語著書種別：学術書

researchmap
多発性骨髄腫診療ハンドブック

瀧澤淳, 他, 飯（担当：共著）

中外医学社 2008年10月

　詳細を見る

記述言語：日本語著書種別：教科書・概説・概論

researchmap
カラーテキスト血液病学

瀧澤淳, 青木定夫（担当：共著）

中外医学社 2007年10月

　詳細を見る

記述言語：日本語著書種別：教科書・概説・概論

researchmap
慢性リンパ性白血病とその類縁疾患の予後予測因子. 特集慢性白血病-最新の診断と治療- Ⅳ. 慢性白血病の予後予測因子

瀧澤淳

日本臨牀社

　詳細を見る

researchmap

▶ 全件表示

MISC

慢性リンパ性白血病におけるハイリスクと初回治療アプローチ招待

瀧澤淳

血液内科 92 ( 2 ) 115 - 123 2026年2月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
その他のがん・悪性腫瘍/造血器腫瘍慢性リンパ性白血病/小リンパ球性リンパ腫招待

瀧澤淳

日本医師会雑誌生涯教育シリーズ108 がん診療2025 154 ( (1) ) S333 - S334 2025年6月

　詳細を見る

担当区分：筆頭著者記述言語：日本語

researchmap
慢性リンパ性白血病の診断と治療招待

瀧澤淳

Medical Practice 42 ( 2 ) 239 - 243 2025年2月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
慢性リンパ性白血病の診断と治療開発の動向招待

瀧澤淳

血液内科 89 ( 5 ) 469 - 475 2024年11月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
慢性リンパ性白血病の最新治療招待

瀧澤淳

腫瘍内科 33 ( 4 ) 341 - 345 2024年4月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
未治療慢性リンパ性白血病に対するacalabrutinib±obinutuzumabの第Ⅲ相試験（ELEVATE-TN試験フォローアップデータ）招待

瀧澤淳

血液内科 88 ( 1 ) 29 - 34 2024年1月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
高齢者に対する造血幹細胞移植招待

瀧澤淳

臨床と研究 101 ( 12 ) 1504 - 1508 2024年

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（学術雑誌）

researchmap
慢性リンパ性白血病におけるMRDの臨床的意義招待

瀧澤淳

血液内科 86 ( 6 ) 775 - 781 2023年6月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
リンパ節微小環境におけるCLL細胞の代謝状態の変化招待

瀧澤淳

血液内科 86 ( 4 ) 560 - 566 2023年4月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
CPC 何が起きていたのか? 最終病理診断からのメッセージ亜急性進行性の巣症状と腎梗塞を併発した66歳の男性

長谷川絵理子, 上條祐司, 岩渕洋平, 下島恭弘, 田澤浩一, 和田庸子, 金澤雅人, 小林大介, 柿田明美, 瀧澤淳, 鋪野紀好, 松本正孝, 須永眞司

日本内科学会雑誌 111 ( 9 ) 1969 - 1985 2022年9月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本内科学会

CiNii Books

J-GLOBAL

researchmap
既治療のハイリスク染色体を有するCLLに対するacalabrutinibとibrutinibのランダム化第Ⅲ相試験（ELEVATE-RR）招待

瀧澤淳

血液内科 84 ( 6 ) 883 - 889 2022年6月

　詳細を見る

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）

researchmap
慢性リンパ性白血病(CLL)と類縁疾患の鑑別診断招待

瀧澤淳, 桐生真依子, 河本啓介

血液フロンティア 28 ( 2 ) 179 - 185 2018年1月

　詳細を見る

記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）出版者・発行元：医薬ジャーナル社

DOI： 10.20837/5201802179

researchmap
単一施設における末梢性T細胞リンパ腫、非特定型の後方視的解析

鈴木隆晴, 河本啓介, 田村秀, 上村駿, 海發茜, 根本洋樹, 小林弘典, 牛木隆志, 布施香子, 柴崎康彦, 森山雅人, 増子正義, 成田美和子, 曽根博仁, 青木定夫, 中村直哉, 大島孝一, 瀧澤淳

臨床血液 58 ( 8 ) 905 - 911 2017年8月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本血液学会-東京事務局

researchmap
慢性リンパ性白血病病態解明の進歩と治療の現在招待査読

瀧澤淳

臨床血液 58 ( 5 ) 471 - 479 2017年5月

　詳細を見る

記述言語：日本語掲載種別：記事・総説・解説・論説等（学術雑誌）出版者・発行元：日本血液学会

<p>慢性リンパ性白血病（CLL）は本邦で希な疾患であるが，欧米では最も頻度の高い成人白血病である。近年の遺伝子解析技術の進歩により，多数の遺伝子変異が確認されているが，疾患特異的な変異は認められず，分子病態的には不均一な疾患群である。その中で<i>TP53</i>，<i>NOTCH1</i>，<i>SF3B</i>，<i>BIRC3</i>などの変異は予後不良因子として重要である。治療は症候性CLLとなった時点で，<i>TP53</i>欠失・変異を確認し，年齢や合併症などからfitnessを把握した上で，化学療法や抗体療法，あるいは，それらの併用療法が選択される。過去数年間に，新規薬剤（B細胞受容体情報伝達系阻害剤やBCL2阻害剤等）の高い有効性と安全性が報告され，欧米で承認されている。本邦は使用できる薬剤が少ない状況が続いていたが，2016年にibrutinibとbendamustineが承認され，ようやく欧米に近い治療が可能になりつつある。</p>

DOI： 10.11406/rinketsu.58.471

PubMed

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2017277000
Comparative Analysis of Japanese and European Typical CLL Patients

Jun Takizawa, Michaela Gruber, Ritsuro Suzuki, Naoya Nakamura, Gregor Hoermann, Leonhard Muellauer, Sadao Aoki, Junji Suzumiya, Ulrich Jaeger

BLOOD 128 ( 22 ) 2016年12月

　詳細を見る

記述言語：英語掲載種別：研究発表ペーパー・要旨（国際会議）

Web of Science

researchmap
単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

田中智之, 上村駿, 海發茜, 田村秀, 諏訪部達也, 片桐隆幸, 河本啓介, 布施香子, 牛木隆志, 柴崎康彦, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

臨床血液 59 ( 9 ) 1678 - 1678 2018年9月

　詳細を見る

記述言語：英語出版者・発行元：(一社)日本血液学会-東京事務局

researchmap
濾胞性リンパ腫初回診断時におけるアグレッシブリンパ腫への形質転換予測(MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma)

桐生真依子, 河本啓介, 鈴木隆晴, 田村秀, 上村駿, 海發茜, 諏訪部達也, 今西明, 笠見卓哉, 根本洋樹, 片桐隆幸, 田中智之, 難波亜矢子, 布施香子, 柴崎康彦, 増子正義, 曽根博仁, 三好寛明, 瀬戸加大, 大島孝一, 瀧澤淳

臨床血液 59 ( 9 ) 1593 - 1593 2018年9月

　詳細を見る

記述言語：英語出版者・発行元：(一社)日本血液学会-東京事務局

researchmap
G-CSFを産生し初回治療中に再発したびまん性大細胞型B細胞性リンパ腫の1例

笠見卓哉, 河本啓介, 鈴木隆晴, 田中智之, 布施香子, 柴崎康彦, 増子正義, 成田美和子, 曽根博仁, 大島孝一, 瀧澤淳

日本リンパ網内系学会会誌 58 114 - 114 2018年5月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本リンパ網内系学会

researchmap
ビタミンD3産生性と考えられるALK陰性未分化大細胞リンパ腫の1例

水戸部正樹, 河本啓介, 鈴木隆晴, 難波亜矢子, 柴崎康彦, 増子正義, 曽根博仁, 三好寛明, 大島孝一, 瀧澤淳

日本リンパ網内系学会会誌 58 121 - 121 2018年5月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本リンパ網内系学会

researchmap
顆粒球肉腫におけるPD-1/PD-L1発現の臨床病理学的検討

河本啓介, 三好寛明, 喜安純一, 佐々木裕哉, 栗田大輔, 鈴木隆晴, 曽根博仁, 瀬戸加大, 瀧澤淳, 大島孝一

日本リンパ網内系学会会誌 57 108 - 108 2017年5月

　詳細を見る

記述言語：日本語出版者・発行元：(一社)日本リンパ網内系学会

researchmap
悪性リンパ腫 : 診断と治療の進歩

瀧澤淳, Takizawa Jun

新潟医学会雑誌 129 ( 10 ) 557 - 561 2015年10月

　詳細を見る

記述言語：日本語出版者・発行元：新潟医学会

悪性リンパ腫は単一の疾患でなく, 様々な分化段階のリンパ球が腫瘍化したもので多数の疾患単位の集合体である. 疾患単位を確定するには生検による病理組織診断が不可欠であるが, 近年の分子生物的解析法の進歩により疾患単位に特徴的な遺伝子異常が明らかにされつつある. これらを標的とした新規薬剤の開発が進んでいる. 特に抗体療法(リツキシマブ: マウス-ヒトキメラ型モノクローナルCD20抗体)の導入により悪性リンパ腫の治療成績は向上した. 2012年以降, 新規抗体薬(イブリツモマブチウキセタン: RI標識抗CD20抗体, モガムリズマブ: 抗CCR4抗体, オファツムマブ: 完全ヒト型モノクローナルCD20抗体, ブレンツキシマブベドチン: 抗CD30抗体薬物複合体)が国内承認され日常臨床に導入されている.

CiNii Article

CiNii Books

researchmap

その他リンク： http://hdl.handle.net/10191/44211
骨髄腫の新しい治療 (シンポジウム血液疾患の治療をめぐる進歩)

瀧澤淳

新潟医学会雑誌 125 ( 2 ) 61 - 64 2011年2月

　詳細を見る

記述言語：日本語出版者・発行元：新潟医学会

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2011220094
高齢者の慢性リンパ性白血病と慢性骨髄性白血病

瀧澤淳, 青木定夫

血液フロンティア 15 ( 9 ) 1489 - 1498 2005年9月

　詳細を見る

記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）出版者・発行元：医薬ジャーナル社

researchmap
薬剤起因性貧血

瀧澤淳

別冊日本臨床領域別症候群シリーズNo.20 413 - 415 1998年8月

　詳細を見る

記述言語：日本語掲載種別：記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）出版者・発行元：日本臨床社

researchmap
成人急性リンパ性白血病における第一寛解期同種骨髄移植群と化学療法群の長期生存率の比較

鈴木訓充, 小池正, 古川達雄, 庭野裕恵, 丸山聡一, 成田美和子, 瀧澤淳, 佐藤直明, 橋本誠雄, 新国公司, 鳥羽健, 岸賢治, 高橋益広, 相沢義房, 柴田昭

臨床血液 = The Japanese Journal of Clinical Hematology 38 ( 1 ) 95 - 99 1997年1月

　詳細を見る

記述言語：日本語出版者・発行元：日本臨床血液学会

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/1997206499

▶ 全件表示

講演・口頭発表等

Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease

Takizawa J., Suzuki R., Izutsu K., Utsunomiya A., Takeuchi K., Nakamura N., Ohshima K., Aoki S., Suzumiya J.

iwCLL (International Workshop on CLL) 2023年6月

　詳細を見る

開催年月日： 2023年6月

記述言語：英語会議種別：ポスター発表

researchmap
Prognosis of Chronic Lymphocytic Leukaemia in Japanese Patients: Results from the CLLRSG-01 Study.

Jun Takizawa, Ritsuro Suzuki, Go Yamamoto, Toru Kiguchi, Atae Utsunomiya, Hideki Asaoku, Eiichi Ohtsuka, Kengo Takeuchi, Koji Izutsu, Naoya Nakamura, Koichi Ohshima, Sadao Aoki, Junji Suzumiya

XIX iwCLL (International Workshop on CLL) 2021年9月

　詳細を見る

開催年月日： 2021年9月

記述言語：英語会議種別：ポスター発表

researchmap
低分子阻害薬(BTK阻害薬，BCL-2阻害薬)を用いたCLLに対する最新治療招待

瀧澤淳

第61回日本リンパ網内系学会総会 2021年6月

　詳細を見る

開催年月日： 2021年6月

記述言語：日本語会議種別：シンポジウム・ワークショップパネル（指名）

researchmap
リンパ腫治療が変わる？重要臨床試験の結果を読み解く「慢性リンパ性白血病」招待

瀧澤淳

日本リンパ網内系学会教育委員会主催リンパ腫エキスパート養成セミナー2019 2019年11月

　詳細を見る

開催年月日： 2019年11月

記述言語：日本語会議種別：公開講演，セミナー，チュートリアル，講習，講義等

researchmap
Expression of LEF1 in Japanese cases of CLL (CLLRSG-01 study)

Takizawa J, Suzuki R, Kawamoto K, Suzuki T, Kiguchi T, Masunari T, Utsunomiya A, Saburi Y, Murakami J, Kitazume K, Suzuki Y, Takeuchi K, Nakamura N, Ohshima, Aoki S, Suzumiya J

XVIII iwCLL (International Workshop on CLL) 2019年9月

　詳細を見る

開催年月日： 2019年9月

記述言語：英語会議種別：ポスター発表

researchmap
Characteristics of chronic lymphocytic leukemia in Japan (CLLRSG-01 study)

Takizawa, J, Suzuki, R, Kiguchi, T, Izutsu, K, Asaoku, H, Saburi, Y, Masunari, T, Utsunomiya, A, Takeuchi, K, Nakamura, N, Ohshima, K, Aoki, S, Suzumiya, J

XVII International Workshop on Chronic Lymphocytic Leukemia 2017年5月

　詳細を見る

開催年月日： 2017年5月

記述言語：英語会議種別：ポスター発表

researchmap
The characteristic of chronic lymphocytic leukemia in Japan: An interim result of CLLRSG-01 study

Takizawa, J, Suzumiya, J, Suzuki, R, Kiguchi, T, Izutsu, K, Asaoku, H, Saburi, Y, Masunari, T, Utsunomiya, A, Nakamura, N, Ohshima, K, Aoki, S

XVI International Workshop on Chronic Lymphocytic Leukemia 2015年9月

　詳細を見る

開催年月日： 2015年9月

記述言語：英語会議種別：口頭発表（一般）

researchmap
リンパ系腫瘍治療の最前線 -Pirtobrutinibの登場で変わる治療戦略- 招待

瀧澤淳

第84回日本癌学会学術総会 2025年9月

　詳細を見る

開催年月日： 2025年9月

記述言語：日本語会議種別：公開講演，セミナー，チュートリアル，講習，講義等

researchmap
未治療CLLに対する新規治療戦略招待

瀧澤淳

第63回日本リンパ網内系学会学術集会・総会 2023年6月

　詳細を見る

開催年月日： 2023年6月

記述言語：ジャワ語会議種別：公開講演，セミナー，チュートリアル，講習，講義等

researchmap

▶ 全件表示

共同研究・競争的資金等の研究

本邦CLLの効果的な治療遂行を目的とした遺伝子解析法の構築

研究課題/領域番号：23K06848

2023年4月 - 2026年3月

制度名：科学研究費助成事業

研究種目：基盤研究(C)

提供機関：日本学術振興会

瀧澤淳

　詳細を見る

配分額：4550000円（直接経費：3500000円、間接経費：1050000円）

わが国で希少疾患である慢性リンパ性白血病（CLL）の実態を明らかにするために、国内47施設で実施した前方視的登録研究（CLLRSG-01）の最終解析を行い、日本人CLL 119例の特徴を明らかにした。他国と同様の自然乾燥塗抹標本による形態診断の結果、FAB分類によるTypical CLL 90例とAtypical CLL 29例に分類されたが、Atypical CLLの頻度は24%であり欧米と同等であることが明らかになった。通説とされていた日本人CLLに形態的なAtypical CLLが多いという概念は、日本特有の強制乾燥塗抹標本を用いた形態観察の結果、細胞が大きい状態で固定されていたものを観察していたためであることが示唆された。次に、Typical CLLとAtypical CLLの特徴を比較したが、Atypical CLLでMatutesスコアが低く、CD13発現例が多いという免疫表現形を除いて、臨床像やdel(17p)/TP53欠失などの染色体/遺伝子異常に有意な違いは認められなかった。近年CLLの病態や治療研究に際して、形態的なTypival CLLとAtypical CLLを分けて議論されることが少なくなっているが、それが妥当であることも確認できた。日本人CLL患者全体の特徴として、予後良好とされるIGHV遺伝子変異例が80%と白人患者に比べて高頻度であることが明らかになった。また、使用されるIGHV遺伝子の種類は、他の東洋諸国と同様でIGHV1の頻度が低く、選択される遺伝子のパターンが欧米と異なることが確認された。以上についてIJH誌に論文発表した。
CLLRSG-01登録の中でBinet Stage Aの早期CLL58例について初回治療開始までの期間（TTFT）に関わる予後因子を解析し、血清可溶性IL-2R 1000U/mL以上とLD正常値超えが予後不良因子となることを明らかにして、国際学会（第20回iwCLL2023）で発表した。
現在まで当科で診断したCLL 30例について、臨床的特徴、一般検査データ、表面形質、染色体異常、FISH解析結果などについて確認し、データベースを作成中である。

researchmap
本邦CLLの病態解明に基づく簡便な新規診断法の確立

研究課題/領域番号：19K07863

2019年4月

制度名：科学研究費助成事業基盤研究(C)

研究種目：基盤研究(C)

提供機関：日本学術振興会

瀧澤淳, 曽根博仁, 大島孝一, 河本啓介

　詳細を見る

担当区分：研究代表者

配分額：4420000円（直接経費：3400000円、間接経費：1020000円）

慢性リンパ性白血病（CLL）は西欧諸国で最も頻度の高い成人白血病であるが、本邦を含めた東アジアでは極めて希少な疾患で、その理由は不明のままである。その原因を解明するために本邦CLLの本態を明確にすることが本研究の目的である。2020年3月まで行ってきた国内前方視登録研究（CLLRSG-01）の登録症例を対象にして研究を行っている。
登録症例に対してフローサイトメトリー（FCM）解析により免疫表現形を解析したが、免疫表現形が典型的（CD5陽性かつCD23陽性のB細胞腫瘍）なCLLと非典型的なCLL-like LPDに分類し、免疫組織化学（IHC）を用いてLEF1発現を検討した。Matutes score 4または5のCLL27例は全例LEF1陽性であったが、score 3のCLLは33例中LEF1陽性は20例（61%）のみで1/3以上がLEF1陰性であることが判明した。CLL-like LPDは21例中8例（38%）がLEF1陽性であり、これらが本当にCLLと異なる疾患であるか更なる検討が必要と考えられた。この検討結果は2019年9月に行われたinternational workshop on CLL (iwCLL2019)に採用され発表を行った。
さらにCLL-like LPDの本態を明らかにするために濾胞辺縁帯B細胞に特徴的な分子と考えられるIRTA1とMNDAの発現についてIHCで検討を行った。陽性コントロールとして用いた濾胞辺縁帯B細胞由来リンパ腫（節性濾胞辺縁帯リンパ腫：NMZL、脾辺縁帯リンパ腫：SMZL、節外性脾辺縁帯MALT型リンパ腫）に発現が認められIHCが機能することが確認され、染色結果を集計している。現在、FISH解析による染色体異常や免疫グロブリン重鎖可変領域（IGHV）の体細胞突然変異（SHM）の有無を含め臨床的および細胞遺伝学的解析結果との比較検討を進めている。

researchmap
CLL希少地域である日本からの挑戦～確実な鑑別診断法の確立と分子病態の解明～

2016年4月 - 2019年3月

制度名：科学研究費助成事業

研究種目：基盤研究(C)

提供機関：日本学術振興会

瀧澤淳

　詳細を見る

担当区分：研究代表者資金種別：競争的資金

配分額：3600000円（直接経費：2520000円、間接経費：1080000円）

researchmap
IgG4関連疾患はMALTリンパ腫の発症原因になり得る

2013年4月 - 2017年3月

制度名：科学研究費助成事業

研究種目：基盤研究(C)

提供機関：日本学術振興会

瀧澤淳, 尾山徳秀

　詳細を見る

担当区分：研究代表者資金種別：競争的資金

配分額：3800000円（直接経費：2660000円、間接経費：1140000円）

researchmap
次世代シークエンサーを用いたＧＭ－ＣＳＦ自己抗体産生機序の解明

2012年4月 - 2015年3月

制度名：科学研究費助成事業

研究種目：基盤研究(B)

提供機関：日本学術振興会

中田光

　詳細を見る

資金種別：競争的資金

researchmap
特発生肺胞蛋白症における免疫変容の体系的研究

2008年4月 - 2011年3月

制度名：科学研究費助成事業

研究種目：基盤研究(B)

提供機関：日本学術振興会

中田光

　詳細を見る

資金種別：競争的資金

researchmap
GM-CSF中和能の新規アッセイ法の確立

2008年4月 - 2010年3月

制度名：科学研究費助成事業

研究種目：挑戦的萌芽研究

提供機関：日本学術振興会

中田光

　詳細を見る

資金種別：競争的資金

researchmap
電磁波障害の無い細胞培養容器への個体認証用ＩＣタグ装着法の開発

2008年1月 - 2008年3月

制度名：科学技術振興機構（JST）平成19年度研究成果実用化検討（FS）課題

提供機関：科学技術振興機構（JST）

　詳細を見る

資金種別：競争的資金

配分額：1000000円（直接経費：900000円、間接経費：100000円）

researchmap

▶ 全件表示

担当経験のある授業科目

内分泌代謝学演習

2026年

-

現在
機関名：新潟大学
臓器別講義・演習I

2025年

-

現在
機関名：新潟大学
臨床医学講義(集中)

2024年

-

現在
機関名：新潟大学